The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney diseases. ASN gratefully acknowledges the following companies for their contributions in 2023.

**DIAMOND LEVEL**

- AstraZeneca
- Novo Nordisk
- Mallinckrodt Pharmaceuticals
- Novo Nordisk
- Baxter Healthcare Corporation
- Fresenius Medical Care

**PLATINUM LEVEL**

- CSL Vifor
- HORIZON.
- Novartis

**GOLD LEVEL**

- Mallinckrodt Pharmaceuticals
- Novo Nordisk

**SILVER LEVEL**

- Amgen
- Ardelyx, Inc.
- Baxter Healthcare Corporation
- Fresenius Medical Care
- Medtronic
- Vera Therapeutics
- Vertex Pharmaceuticals

**BRONZE LEVEL**

- Apellis Pharmaceuticals
- Aurinia Pharmaceuticals
- Bayer
- bioMérieux
- Dialy
t
- Lilly USA
- Natera
- Omeros
- Boehringer Ingelheim Pharmaceuticals, Inc.

As of September 1, 2023
Attention US Health Professionals -- To ensure full compliance with the Open Payments (Physician Payments Sunshine Act), a provision of the Patient Protection and Affordable Care Act (PL 111-148) that requires applicable manufacturers and applicable group purchasing organizations to report financial payments made to US physicians and select other US health care professionals, including as part of supported ASN activities. ASN reserves the right to provide information to such entities about US physicians, US physician assistants, and US advanced practice nurses (and their spouses) who participate in selected ASN activities.

Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain health care providers. ASN makes reasonable attempts to collect and maintain the following information about its US physician members: 1) name and business address, 2) specialty, 3) National Provider Identification (NPI) number, and 4) state(s) professional license number and name of state(s) issuing license.

In the event that ASN receives payment from an applicable sponsor and the sponsor requests the reportable information from ASN, ASN will provide the information under the condition that the sponsor agrees to use the data only for reporting purposes covered under the Act and no other purpose.

US physicians have certain rights under this Act, and more information about these rights can be found at the resources listed below.

To learn more, please go to the US Government’s Center for Medicare & Medicaid Services (CMS) website, www.cms.gov/openpayments. Additional information can be found at the American Medical Association’s website.
Download the Kidney Week Mobile App

Navigate the meeting like a pro with the meeting mobile app.

• Stay organized with current session, exhibitor, and meeting information.
• Receive important real-time communications from ASN.
• Build a personalized schedule and bookmark exhibitors.
• Stay in-the-know and join the social media conversation.
• And more!

GET THE FREE APP SEARCH FOR “ASN KIDNEY WEEK”

The Kidney Week Mobile App is supported by CHINOOK THERAPEUTICS
A Novartis Company
Welcome to ASN Kidney Week 2023

ASN proudly welcomes you to Kidney Week, the world’s premier nephrology meeting.

At Kidney Week, the world’s leading experts share new approaches to health care, research, education, and policy. Participants have opportunities to network with fellow specialists, advance their careers, learn best practices for treating and improving the lives of people with kidney diseases, and collaborate with colleagues from around the world.

Leading the fight against kidney diseases for over 50 years, ASN represents health professionals whose intellectual rigor, integrity, and ingenuity advance kidney research, treatment, and policy and improve the lives of millions of patients.

ASN Council
Michelle A. Josephson, MD, FASN, President
Susan E. Quaggin, MD, FASN, Past President
Deidra C. Crews, MD, MS, FASN, President-Elect
Prabir Roy-Chaudhury, MD, PhD, FASN, Secretary
Keisha L. Gibson, MD, MPH, FASN, Treasurer
Jeffrey S. Berns, MD, FASN, Councilor
Linda F. Fried, MD, MPH, FASN, Councilor
Crystal A. Gadegbeku, MD, FASN, Councilor
Patrick H. Nachman, MD, FASN, Councilor

Kidney Week Education Committee
Dianne B. McKay, MD, Co-Chair
Mark A. Perazella, MD, MS, FASN, Co-Chair
Reza Abdi, MD
Matthew K. Abramowitz, MD, MS, FASN
George L. Bakris, MD, MA, FASN
Nisha Bansal, MD, FASN
Erin F. Barreto, PharmD, MS, FASN
Mounita Barua, MD
Whitney Besse, MD
Hui Cai, MD, FASN
Corey J. Cavanaugh, DO
Jordan B. Cohen, MD, MS, FASN
Mark E. Cooper, MBBS, PhD, FASN
Stanley D. Crittenden, MD, FASN
Donald Fraser, MBChB, PhD
Lorenzo G. Gallon, MD
Rasheed A. Gbadegesin, MBBS, MD, FASN
Orlando M. Gutierrez, MD
Gentzon Hall, MD, PhD
Takashi Hato, MD
Leal C. Herlitz, MD
Jeffrey B. Hodgin, MD, PhD
Tamara Isakova, MD
Beom Seok Kim, MD, PhD
Lisa A. Koester Wiedemann, ANP, CNN-NP
Rachel Lennon, MBBS, PhD
Helen McNeill, PhD
Patrick T. Murray, MD, FASN
Monika A. Niewczas, MD, PhD, MPH
Samir M. Parikh, MD, FASN
Tammy L. Sirich, MD, FASN
Arohan R. Subramanya, MD, FASN
Smitha R. Vidi, MD
David M. White
Anna L. Zisman, MD, FASN
## Schedule-at-a-Glance

<table>
<thead>
<tr>
<th>Thursday, November 2</th>
<th>AM</th>
<th>6:30</th>
<th>7:00</th>
<th>7:30</th>
<th>8:00</th>
<th>8:30</th>
<th>9:00</th>
<th>9:30</th>
<th>10:00</th>
<th>10:30</th>
<th>11:00</th>
<th>11:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific Exposition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Friday, November 3**

<table>
<thead>
<tr>
<th>AM</th>
<th>6:30</th>
<th>7:00</th>
<th>7:30</th>
<th>8:00</th>
<th>8:30</th>
<th>9:00</th>
<th>9:30</th>
<th>10:00</th>
<th>10:30</th>
<th>11:00</th>
<th>11:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific Exposition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Saturday, November 4**

<table>
<thead>
<tr>
<th>AM</th>
<th>6:30</th>
<th>7:00</th>
<th>7:30</th>
<th>8:00</th>
<th>8:30</th>
<th>9:00</th>
<th>9:30</th>
<th>10:00</th>
<th>10:30</th>
<th>11:00</th>
<th>11:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific Exposition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sunday, November 5**

<table>
<thead>
<tr>
<th>AM</th>
<th>6:30</th>
<th>7:00</th>
<th>7:30</th>
<th>8:00</th>
<th>8:30</th>
<th>9:00</th>
<th>9:30</th>
<th>10:00</th>
<th>10:30</th>
<th>11:00</th>
<th>11:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenary Session and ASN Business Meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Legend**

- **BCSS** - Basic/Clinical Science Sessions
- **CPS** - Clinical Practice Sessions
- **TS** - Translational Sessions
- **SS** - Special Sessions

*Program is subject to change.*
| Time  | PM 12:00 | 12:30 | 1:00 | 1:30 | 2:00 | 2:30 | 3:00 | 3:30 | 4:00 | 4:30 | 5:00 | 5:30 | 6:00 | 6:30 | 7:00 |
|-------|----------|-------|------|------|------|------|------|------|------|------|------|------|------|------|
| Sat.  |          |       |      |      |      |      |      |      |      |      |      |      |      |      |
|       |          |       |      |      |      |      |      |      |      |      |      |      |      |      |
| Sun.  |          |       |      |      |      |      |      |      |      |      |      |      |      |      |
| EDT to EST Time Change Sunday, November 5 |
| Don't forget to turn back your clocks one hour. |
Accreditation, CE Credits, MOC Points
(Annual Meeting, November 2–5)

Learning Objectives
At the conclusion of this activity, participants will have increased knowledge in the field of nephrology and will be able to:
1. Identify recent discoveries in basic, translational, and clinical research in nephrology.
2. Construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines.
3. Translate recent advances in the areas of general nephrology, dialysis, transplantation, and hypertension into new standards and approaches to clinical care of patients with kidney diseases and related disorders.

Target Audience
- Physicians
- PhDs and Other Researchers
- Medical and Other Trainees—including medical students, residents, graduate students, post-docs, and fellows
- Nurses and Nurse Practitioners
- Pharmacists
- Physician Assistants
- Other Health Care Professionals

Accreditation Statement
In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Medical Education Credits
AMA CREDIT DESIGNATION STATEMENT – PHYSICIANS
The American Society of Nephrology designates this blended learning activity for a maximum of 75.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC CREDIT DESIGNATION STATEMENT – NURSES
This CE activity is approved for 75.0 ANCC contact hours.

ACPE CREDIT DESIGNATION STATEMENT – PHARMACISTS
This activity has been approved for 75.0 contact hours.

AAPA/NCCPA CREDIT DESIGNATION STATEMENT – PHYSICIAN ASSISTANTS
Physician Assistants may claim a maximum of 75.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

ASN values each participant’s review and comments on the quality of ASN’s educational activities. Please complete the evaluation, claim credits, and claim MOC at www.asn-online.org/elearning by December 20, 2023. Instructions are available on the ASN website and at ASN Services on the Bridge between the Grand Hall and Exhibit Halls in the convention center.

Note: For Early Program credits, please refer to the program materials.
Maintenance of Certification (MOC) Points
The Kidney Week Annual Meeting offers MOC Points for American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) Diplomates with the completion of a reflective statement and commitment-to-change questions in this activity’s evaluation. Instructions are available on the ASN website and ASN eLearning Center.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 75 MOC points in the ABIM Maintenance of Certification (MOC) program; and
- 75 MOC points in the ABP Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Statement from ABIM
This course has been developed as an original and independent educational offering based on the public ABIM examination blueprint and is not approved or endorsed by ABIM. In accordance with ABIM policy, no ABIM Board members have been involved in the development of this course. ASN cannot guarantee that attending this course will result in passing the ABIM examination.

Disclosure Statement
It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN’s sponsored continuing education (CE) activities are expected to provide full disclosure for both themselves and their spouse/partner, and to indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the previous 12 months. Furthermore, ASN requests all faculty to disclose at the time of their lecture any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their presentation. Participants should note that the use of products outside US Food and Drug Administration (FDA)–approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CE, but rather to ensure that ASN CE activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for Kidney Week to complete disclosure forms. Responses are listed on the ASN website, in the meeting platform, and during sessions.

Certificates of Attendance for International Participants
Early Program participants can pick up printed Certificates of Attendance (not CME certificates for US participants) on Wednesday, November 1 at the programs. Annual Meeting participants can access online Certificates of Attendance (not CME certificates for US participants) from November 2, 2023, through February 2, 2024, at https://show.jspargo.com/asn23/certificateofAttendance/. Certificates are only available if you have picked up your meeting materials or printed your meeting badge onsite. If you have questions, please visit ASN Services on the Registration Bridge of the convention center.
Visit the ASN Communities Lounge at ASN Kidney Week
Community discussions, networking, and collaboration.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday, Nov. 2</strong></td>
<td><strong>Overview of Communities</strong> 11:00 a.m. — 12:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>Profile components, account preferences, navigation tips</td>
</tr>
<tr>
<td></td>
<td><strong>Mentor Match Program</strong> 12:00 p.m. — 1:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>Enrollment basics, search criteria, building relationships</td>
</tr>
<tr>
<td></td>
<td><strong>Networking and Collaboration</strong> 1:00 p.m. — 2:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>Leveraging connections, sharing stories, team projects</td>
</tr>
<tr>
<td><strong>Friday, Nov. 3</strong></td>
<td><strong>CMMI Listening Session</strong> 10:00 a.m. — 11:00 a.m.</td>
</tr>
<tr>
<td></td>
<td>Join the Center for Medicare and Medicaid Innovation (CMMI) and ASN</td>
</tr>
<tr>
<td></td>
<td>to discuss the ESRD Treatment Choices (ETC) Model and the Kidney</td>
</tr>
<tr>
<td></td>
<td>Care Choices (KCC) Model.</td>
</tr>
<tr>
<td></td>
<td><strong>Hot Topics</strong> 11:00 a.m. — 12:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>Chronic Kidney Disease, Transplantation, Home Dialysis</td>
</tr>
<tr>
<td></td>
<td><strong>Becoming a Community Leader</strong> 12:00 p.m. — 1:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>Engagement strategies, moderation, replies, and follow-through</td>
</tr>
<tr>
<td></td>
<td><strong>CMMI Listening Session</strong> 1:00 p.m. — 2:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>Join CMMI representatives and ASN staff to ask questions and</td>
</tr>
<tr>
<td></td>
<td>discuss issues regarding the ETC Model and KCC Model.</td>
</tr>
<tr>
<td><strong>Saturday, Nov. 4</strong></td>
<td><strong>Communities Library</strong> 10:00 a.m. — 11:00 a.m.</td>
</tr>
<tr>
<td></td>
<td>Keyword searching, studies &amp; reports, credible research</td>
</tr>
<tr>
<td></td>
<td><strong>Early Career Focus</strong> 11:00 a.m. — 12:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>STARS, TREKS, in-training exam, the nephrology match</td>
</tr>
<tr>
<td></td>
<td><strong>Themed Communities</strong> 12:00 p.m. — 1:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>Onco-nephrology, Kidney Transplantation, Women’s Health &amp; Research</td>
</tr>
<tr>
<td></td>
<td><strong>Open Discussion</strong> 1:00 p.m. — 2:00 p.m.</td>
</tr>
<tr>
<td></td>
<td>New ideas, future directions, lingering questions</td>
</tr>
</tbody>
</table>

Meet-and-Greet 10:00 a.m. — 11:00 a.m.

Ed Kashi
Photojournalist and Filmmaker

CMMI Listening Session
Join the Center for Medicare and Medicaid Innovation (CMMI) and ASN to discuss the ESRD Treatment Choices (ETC) Model and the Kidney Care Choices (KCC) Model.

Hot Topics
Chronic Kidney Disease, Transplantation, Home Dialysis

Becoming a Community Leader
Engagement strategies, moderation, replies, and follow-through

CMMI Listening Session
Join CMMI representatives and ASN staff to ask questions and discuss issues regarding the ETC Model and KCC Model.

Listen and partake in conversations.
DAY-AT-A-GLANCE
Wednesday, November 1

Early Programs
Each Early Program requires separate registration from the Annual Meeting.
Detailed schedules are available at each Early Program room.

7:00 a.m. Onsite Check-In and Continental Breakfast for all 7 Early Programs

Advances in Research Conference: Multi-Omic Analyses of Tissue Microenvironments in the Kidneys ................................................................. Room 108
8:00 a.m. Onsite Sessions
4:45 p.m. Adjourn

Fundamentals of Renal Pathology ............................................................................................................. Room 109
8:00 a.m. Onsite Sessions
5:30 p.m. Adjourn

Genetics in Clinical Nephrology ............................................................................................................... Room 107
8:00 a.m. Onsite Sessions
5:30 p.m. Adjourn

Glomerular Diseases: 2023 Update ........................................................................................................ Ballroom B
Support is provided by an educational grant from Vera Therapeutics.
8:00 a.m. Onsite Sessions
5:40 p.m. Adjourn

Kidney Transplantation: 2023 Update ..................................................................................................... Ballroom A
In cooperation with the American Society of Transplantation.
8:00 a.m. Onsite Sessions
5:10 p.m. Adjourn

Maintenance Dialysis: 2023 Update ......................................................................................................... Room 204
8:00 a.m. Onsite Sessions
5:00 p.m. Adjourn

Nephrocardiology: An Emerging Field in Medicine ............................................................................. Room 201
8:00 a.m. Onsite Sessions
6:00 p.m. Adjourn

All Early Programs except the Advances in Research Conference have on-demand presentations that have been available for viewing in the ASN eLearning Center since October 25.

Download the Kidney Week App
For up-to-date meeting information, search Kidney Week in your app store or scan the QR code here.
Exhibitor Spotlight Schedule

Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in two theaters on the exhibit hall floor (no continuing education credit). Seating is limited and available on a first-come, first-served basis.

The 10:00 a.m. presentation includes breakfast. All other presentations include lunch.

Thursday, November 2
10:00 a.m. - 10:45 a.m.
The Dual Dilemma: Navigating Cardiorenal Risk in CKD Associated with T2D

Presented by Bayer

12:00 p.m. - 12:45 p.m.
Replacing RASi in IgA Nephropathy: Unique Therapy Targets Two Pathways, with a Patient’s Perspective

Presented by Traverese Therapeutics

Friday, November 3
10:00 a.m. - 10:45 a.m.
Guideline Considerations for Early Treatment in Lupus Nephritis & Updates on Anemia of CKD

Presented by GSK

12:00 p.m. - 12:45 p.m.
Overcoming the Challenges of Phosphate Management with a High-Potency Approach

Presented by Fresenius Medical Care

Saturday, November 4
10:00 a.m. - 10:45 a.m.
Understanding the Complexity of Patients With CKD: Implications for Management

Presented by AstraZeneca

12:00 p.m. - 12:45 p.m.
Jardiance® (empagliflozin) tablets: A Peer Review of the Latest Clinical Data and Dosing Recommendations

Presented by Boehringer Ingelheim and Lilly
Thursday, November 2
11:00 a.m. - 11:45 a.m.
IgA Nephropathy: Where We Are Now and Where We Are Going

Presented by  

1:00 p.m. - 1:45 p.m.
Terlipressin and Albumin Use in Hepatorenal Syndrome

Presented by  

Friday, November 3
11:00 a.m. - 11:45 a.m.
A New Paradigm: Rethinking Hyperphosphatemia Management

Presented by  

1:00 p.m. - 1:45 p.m.
Early Identification and Management in ADPKD
Featuring Dialogue With a Patient Ambassador

Presented by  

Saturday, November 4
11:00 a.m. - 11:45 a.m.
A Closer Look at Kidney Preservation in Lupus Nephritis

Presented by  

1:00 p.m. - 1:45 p.m.
Genetics in Nephrology: What Are We Missing?

Presented by  

These events are not CE (continuing education) activities.
DAY-AT-A-GLANCE
Thursday, November 2

8:00 a.m. – 9:30 a.m.
Opening Plenary: ASN President’s Address, ASN President’s Medal, Murphy Award,
State-of-the-Art Lecture................................................................................................. Hall A

9:30 a.m. – 2:30 p.m.
Morning Break (9:30 a.m. – 10:00 a.m.)............................................................................ Exhibit Hall C
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)...................................................... Exhibit Hall C
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.).................................................. Exhibit Hall C

10:00 a.m. – 1:45 p.m.
Exhibitor Spotlights ........................................................................................................... Exhibit Hall C

Please see pages 10-11 for the schedule and topics.

10:30 a.m. – 12:30 p.m.
Basic/Clinical Science Sessions
APOL1 and Kidney Transplantation .................................................................................. Room 115
Best of ASN Journals: JASN, CJASN, and Kidney360 ........................................................... Ballroom B
Chloride Channels: Physiologic and Pathophysiologic Relevance ........................................ Room 114 (Nutter Theatre)

Clinical Practice Sessions
Artificial Intelligence and Its Promise to Complement AKI Care ........................................ Room 201
Let's Make It Better: Improving Home Dialysis Therapy..................................................... Room 113
Present and Future: Hypertension and Cardiovascular Risk Prediction in Children ............ Room 108
Screening for Kidney Diseases: A Call to Action ............................................................... Room 120
Social Determinants of BP and CVD in Patients with CKD ................................................... Room 118
Therapeutic Dilemmas in Glomerular Diseases ..................................................................... Room 204

Translational Sessions
Biomarker Studies in Lupus Nephritis: A New Opportunity for Precision Medicine ............ Room 103
Changing Landscape of Diabetic Kidney Disease Treatment,
with the Schrier Endowed Lectureship ............................................................................. Ballroom A
Vascular Calcification: Mechanisms, Outcomes, and Emerging Treatment Options .............. Room 119

Other Event
Fellows-in-Training Bowl: Elimination Rounds .................................................................. Exhibit Hall C

12:45 p.m. – 1:45 p.m.
Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)
Doors open at 12:30 p.m.
Anemia in CKD and ESKD: From Epidemiology and Pathophysiology to Current Treatments ...... Salon I
Real-World Management of Hyperkalemia in Cardiorenal Patients ........................................ Salon D
What’s New with SGLT2 Inhibitors in 2023 ........................................................................ Salon A

1:00 p.m. – 2:00 p.m.
Top Trainee Posters ........................................................................................................... Exhibit Hall C

2:00 p.m. – 4:00 p.m.
Basic/Clinical Science Sessions
Clinical Trials in Pediatric CKD: Trial with SGLT2 Inhibitors? ............................................. Room 108
Developments in AKI and Repair Mechanisms ..................................................................... Room 201
Innovative Strategies for Visualization of the Glomerular Basement Membrane:
New Views of an Old Neighborhood ................................................................................ Room 103
Integrating Kidney Genetics into Clinical Practice .............................................................. Room 107
### 2:00 p.m. – 4:00 p.m.

#### Basic/Clinical Science Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Targets in Diabetic Kidney Disease: Experimental Studies</td>
<td>Room 120</td>
</tr>
<tr>
<td>Nutrition, Metabolism, and Cardiovascular Risk in Dialysis</td>
<td>Room 114</td>
</tr>
<tr>
<td>Organoids with PKD: Defining What They Are and What They Can Do for Us</td>
<td>Room 105</td>
</tr>
<tr>
<td>Precision Medicine Approaches for Renal Osteodystrophy</td>
<td>Room 121</td>
</tr>
<tr>
<td>Selecting Kidney Donors: Challenges in Evaluating the Appropriate Candidate</td>
<td>Room 115</td>
</tr>
<tr>
<td>Transport Mechanisms Along the Renal Tubule: Legacy of Moe Burg</td>
<td>Room 111</td>
</tr>
</tbody>
</table>

#### Clinical Practice Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosing Hemodialysis: One Size Does Not Fit All, with the Eknoyan Endowed Lectureship</td>
<td>Room 113</td>
</tr>
<tr>
<td>Updates in Membranous Nephropathy: My Antigen Teacher</td>
<td>Room 204</td>
</tr>
</tbody>
</table>

#### Translational Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic Kidney Disease Across the Lifespan: Joint ASN-ADA Session</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>My Patient Is Weak and Frail: What Can I Do About It?</td>
<td>Room 109</td>
</tr>
<tr>
<td>New Directions in Hypertension Treatment</td>
<td>Ballroom B</td>
</tr>
</tbody>
</table>

#### Special Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shovel-Ready Opportunities to Transform Kidney Transplantation in the United States</td>
<td>Room 118</td>
</tr>
<tr>
<td>When the Patient Becomes the Teacher: Exploring the Intersections of Disability and Kidney Diseases</td>
<td>Room 119</td>
</tr>
</tbody>
</table>

**4:00 p.m. – 4:30 p.m.**

Afternoon Break

**4:30 p.m. – 6:00 p.m.**

#### Clinical Practice Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver-Kidney Connection: Time to Rethink Hepatorenal Syndrome</td>
<td>Room 201</td>
</tr>
<tr>
<td>Recurrent Glomerulonephritis After Kidney Transplantation</td>
<td>Room 114</td>
</tr>
<tr>
<td>Women's Health and the Kidneys</td>
<td>Room 204</td>
</tr>
</tbody>
</table>

#### Special Session

<table>
<thead>
<tr>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health Care Equity in Education, Clinical Care, and Community Engagement</td>
<td>Room 113</td>
</tr>
</tbody>
</table>

#### Oral Abstract Sessions

<table>
<thead>
<tr>
<th>Session</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKI Mechanisms: Cellular and Organ Cross-Talk</td>
<td>Room 118</td>
</tr>
<tr>
<td>CKD Mechanisms: Prediction, Propagation, and Prevention</td>
<td>Room 119</td>
</tr>
<tr>
<td>Glomerular Diseases: Clinical and Translational Studies</td>
<td>Room 103</td>
</tr>
<tr>
<td>Hemodialysis Care: Quality, Vascular Access, and Emerging Threats</td>
<td>Room 120</td>
</tr>
<tr>
<td>Improving Clinical Outcomes in Diabetic Kidney Disease</td>
<td>Room 121</td>
</tr>
<tr>
<td>Investigations in Polycystic and Tubulointerstitial Kidney Diseases</td>
<td>Room 105</td>
</tr>
<tr>
<td>Mechanisms and Single-Cell Transcriptional Profiles in Transplant Rejection and Ischemia Reperfusion Injury</td>
<td>Room 115</td>
</tr>
<tr>
<td>Mechanisms of Hypertension and Cardiorenal Disease: From the Vasculature to the Gut</td>
<td>Room 108</td>
</tr>
<tr>
<td>Onconephrology and Precision Pharmacology</td>
<td>Room 107</td>
</tr>
<tr>
<td>Research Advances in Bone and Mineral Metabolism</td>
<td>Room 111</td>
</tr>
</tbody>
</table>

**6:00 p.m. – 7:00 p.m.**

Welcome Reception

---

Download the Kidney Week App for up-to-date meeting information, search Kidney Week in your app store or scan the QR code here.
Thursday, November 2, 8:00 a.m. – 9:30 a.m.

Opening Plenary
8:00 a.m. ASN President’s Address – Michelle Josephson
8:30 a.m. ASN President’s Medal – Ed Kashi
8:50 a.m. Barbara T. Murphy Award – Rulan Parekh
9:00 a.m. State-of-the-Art Lecture “Tiny Conspiracies: Cell-to-Cell Communication in Bacteria and New Approaches to Antimicrobials” – Bonnie Bassler

Thursday, November 2, 10:30 a.m. – 12:30 p.m.

APOL1 and Kidney Transplantation
Moderators: Maria Safar-Boueri, Deirdre Sawinski
10:30 a.m. Patient Perspective on APOL1 in Kidney Transplantation – Glenda Roberts
11:00 a.m. APOL1 in Deceased Donor Kidney Transplantation – Barry Freedman
11:30 a.m. APOL1 in the Evaluation and Selection of Living Kidney Donors – Mona Doshi
12:00 p.m. Recipient APOL1 Genotype Effects in Kidney Transplantation – Madhav Menon

Best of ASN Journals: JASN, CJASN, and Kidney360
Moderators: Tarek El-Achkar, Morgan Grams
10:35 a.m. My Vision for the ASN Journal Portfolio – Rajnish Mehrotra
10:45 a.m. New Insights into Care of the Transplant Patient – John Gill
11:20 a.m. Genetic Diseases of the Kidneys – Michel Chonchol
11:55 a.m. Advances in CKD and Dialysis – Jennifer Flythe

Chloride Channels: Physiologic and Pathophysiologic Relevance
Moderators: Hui Cai, Andrew Terker
10:30 a.m. Novel Roles of CIC-Kb Chloride Channel in Collecting Duct Intercalated Cells – Oleh Pochynyuk
11:00 a.m. Electrogenic Exchanger ClC5 as a Novel Player in Renal Cysts in Tuberous Sclerosis – Grazia Tamma
11:30 a.m. Impairment in Renal Medulla Development Underlies Salt Wasting in ClCK2 Channel Deficiency – Chih-Jen Cheng
12:00 p.m. Chloride Transport Modulators as Drug Candidates – Onur Cil

Artificial Intelligence and Its Promise to Complement AKI Care
Moderators: Javier Neyra, Danielle Soranno
10:30 a.m. Machine Learning, AI, and Deep Learning: How to Make Sense of the Language Being Used – Girish Nadkarni
11:00 a.m. Beyond AKI: How Is AI Improving Care in Critical Illness? – Azra Bihorac
11:30 a.m. Not Your Father’s Risk Score: Dynamic Risk Assessment and Alerts for AKI – Jay Koyner
12:00 p.m. Let the Algorithm Decide the Dose: AI-Guided Dosing in AKI – Todd Miano

Program is subject to change.
Thursday, November 2, 10:30 a.m. – 12:30 p.m.

**Let’s Make It Better: Improving Home Dialysis Therapy** ..................................................... Room 113
Moderators: Precious McCowan, Rebecca Seshasai
10:30 a.m.  
**A Patient’s Perspective: What a Patient Wants to Know About Home Dialysis** – Vanessa Evans
11:00 a.m.  
**Which One: CAPD vs. APD** – Michael Kraus
11:30 a.m.  
**Let’s Stay Home: A Look into Keeping Patients at Home** – Christopher Chan
12:00 p.m.  
**Seamless Transition: Transitioning the Pediatric Patient to Home Hemodialysis** – Sarah Swartz

**Present and Future: Hypertension and Cardiovascular Risk Prediction in Children** .... Room 108
Moderators: Kevin Meyers, Christine Sethna
10:30 a.m.  
**Novel Risk Factors for Neonatal Hypertension and Future Directions** – Janis Dionne
11:00 a.m.  
**Predictors of Target Organ Damage in Youth: SHIP-AHOY** – Elaine Urbina
11:30 a.m.  
**Novel Biomarkers for Cardiovascular Risk Assessment in Pediatrics** – Manish Sinha
12:00 p.m.  
**Machine Learning for Developing Prediction Models in Pediatric Hypertension and Kidney Diseases** – Sunjae Bae

**Screening for Kidney Diseases: A Call to Action** ................................................................. Room 120
Moderators: Susan Quaggin, Matthew Weir
10:30 a.m.  
**Practical Models to Collaborate with Primary Care to Screen for Kidney Diseases** – Lesley Inker
11:00 a.m.  
**Economical and Health Consequences of Current Screening Patterns for Kidney Diseases** – Marika Cusick
11:30 a.m.  
**Missed Opportunity? Screening for Kidney Diseases in Children and Young Adults** – Joseph Flynn
12:00 p.m.  
**Screening for Kidney Diseases: A Patient’s Perspective** – Morgan Reid

**Social Determinants of BP and CVD in Patients with CKD** .................................................. Room 118
Moderators: Dinushika Mohottige, Julia Scialla
10:30 a.m.  
**Structural Racism and the Neighborhood Environment in Patients with CKD and Hypertension** – Anika Hines
11:00 a.m.  
**Social Determinants of BP Among Hispanic Communities** – Tali Elfassy
11:30 a.m.  
**Race, Biomarkers, and CVD in Patients with CKD** – Susanne Nicholas
12:00 p.m.  
**Barriers to Adequate Care and Resulting Inequities in Hypertension Control** – Joseph Lunyera

**Therapeutic Dilemmas in Glomerular Diseases** ................................................................. Room 204
*Support is provided by an educational grant from Travere Therapeutics, Inc.*
Moderators: Tingting Li, Shikha Wadhwani
10:30 a.m.  
**Appropriate Use of Glucocorticoids in IgA Nephropathy** – Richard Lafayette
11:00 a.m.  
**Can Rituximab Replace the Modified Ponticelli Regimen in Membranous Nephropathy?** – Laurence Beck
11:30 a.m.  
**When Glucocorticoids Are Not Enough: Approach to Steroid-Resistant FSGS** – Laura Mariani
12:00 p.m.  
**SGLT2 Inhibitors in Primary Glomerulopathies: Is It Time?** – Paola Romagnani
Thursday, November 2, 10:30 a.m. – 12:30 p.m.

Biomarker Studies in Lupus Nephritis: A New Opportunity for Precision Medicine ....... Room 103
Moderators: Jeffrey Hodgin, Cynthia Nast
10:30 a.m.  Overview and Clinical Utility of Biomarkers in Lupus Nephritis – Dawn Caster
11:00 a.m.  Application of Single-Cell RNA Sequencing in Molecular Profiling of Lupus Nephritis – Arnon Arazi
11:30 a.m.  Renal Pathologic Correlates of Biomarker and Molecular Studies – Ingeborg Bajema
12:00 p.m.  Current Biologic-Targeted Therapies in Lupus Nephritis – George Bertsias

Changing Landscape of Diabetic Kidney Disease Treatment, Including the Robert W. Schrier, MD, Endowed Lectureship............................................ Ballroom A
ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Schrier Endowed Lectureship.
Moderators: Sylvia Rosas, Katherine Tuttle
11:00 a.m.  Unmet Treatment Needs for Diabetic Kidney Disease – Linda Fried
11:30 a.m.  Are SGLT2 Inhibitors New Again? – William Herrington
12:00 p.m.  GLP1 Receptor Agonists: On the Mechanism – Daniel Drucker

Vascular Calcification: Mechanisms, Outcomes, and Emerging Treatment Options ....... Room 119
Moderators: Wei Chen, Jason Stubbs
10:30 a.m.  New Insights into the Pathophysiology of Vascular Calcification – Abolfazl Zarjou
11:00 a.m.  Burden of Vascular Calcification in CKD: Epidemiology and Outcomes – Tara Chang
11:30 a.m.  Evolution of Calcemic Uremic Arteriolopathy: Risk Factors and Treatments – Sagar Nigwekar
12:00 p.m.  Landscape of Potential Therapeutics for Vascular Calcification: From Old to New – Marc Vervloet

Fellows-in-Training Bowl: Elimination Rounds.................................Futures Theater - Exhibit Hall C
Support is provided by Calliditas Therapeutics.
Note: Continuing education credits are not being offered for this activity.
**Thursday, November 2, 12:45 p.m. – 1:45 p.m.**

**Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)**

Doors open at 12:30 p.m. Lunch is provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Anemia in CKD and ESKD: From Epidemiology and Pathophysiology to Current Treatments

Support is provided by an educational grant from GSK.

12:45 p.m. **Introduction: Overview of the Epidemiology of Anemia in CKD – Neeraj Sharma (Moderator)**
12:55 p.m. **Mechanisms of Anemia in Kidney Diseases – Kirsten Johansen**
1:15 p.m. **Optimal Anemia Management in CKD and ESKD – Daniel Coyne**
1:35 p.m. Questions and Answers

Real-World Management of Hyperkalemia in Cardiorenal Patients

Support is provided by an educational grant from CSL Vifor.

12:45 p.m. **Introduction – Joshua Rein (Moderator)**
12:55 p.m. **Advances in the Regulation of Potassium Homeostasis by RAAS and Other Hormonal Factors – Paul Welling**
1:15 p.m. **Updated Management of Chronic Hyperkalemia in Cardiorenal Patients: A Practical Approach – Csaba Kovesdy**
1:35 p.m. Questions and Answers

What’s New with SGLT2 Inhibitors in 2023

Support is provided by an educational grant from AstraZeneca.

12:45 p.m. **Introduction – Steven Coca (Moderator)**
12:55 p.m. **Moving Toward Goal-Directed Medical Therapy in CKD: Updates in SGLT2 Inhibitors and Use with Other Novel Therapies – Ian de Boer**
1:15 p.m. **Pearls and Pitfalls of Implementing SGLT2 Inhibitors to the Bedside – Aisha Shaikh**
1:35 p.m. Questions and Answers

**Thursday, November 2, 2:00 p.m. – 4:00 p.m.**

Clinical Trials in Pediatric CKD: Trial with SGLT2 Inhibitors?

ASN thanks the Kidney Health Initiative for assistance with this session.

Moderators: Susan Furth, William Herrington

2:00 p.m. **Designing Trials in Pediatric CKD: Hurdles and Solutions – William Smoyer**
2:30 p.m. **Journey Through CKD: A Family’s Perspective – Austin Lee, Clarissa Lee**
3:00 p.m. **SGLT2 Inhibitors and Kidneys: What We Know So Far – Marva Moxey-Mims**
3:30 p.m. **Conceptual Model for Pediatric Trials: SGLT2 Inhibitors in Children with CKD – Zubin Modi**

Developments in AKI and Repair Mechanisms

Moderators: Subhashini Bolisetty, Lloyd Cantley

2:00 p.m. **Healthy and Injured Cell States in the Human Kidney – Matthias Kretzler**
2:30 p.m. **Cell Death to Efferocytosis: Clearing the Way for Recovery – Sho Morioka**
3:00 p.m. **Long-Term Cell Fate After AKI: Tracing the Way Forward – Louisa Gerhardt**
3:30 p.m. **Maladaptive Repair, Dedifferentiation, and Cell Senescence – Craig Brooks**
Thursday, November 2, 2:00 p.m. – 4:00 p.m.

Innovative Strategies for Visualization of the Glomerular Basement Membrane: New Views of an Old Neighborhood ................................................................. Room 103

Support is provided by an educational grant from Travere Therapeutics, Inc.

Moderators: Jennie Lin, Lori O’Brien

2:00 p.m. Watching Their Steps: Visualizing Podocyte Processes on Micropatterned Substrates – Hani Suleiman
2:30 p.m. Using Intravital Imaging to Probe the Mechanisms of Collagenopathy – Janos Peti-Peterdi
3:00 p.m. Don’t Forget to Stretch: New Views of the Filtration Barrier with Expansion Microscopy – Lorenz Sellin
3:30 p.m. Up Close and Personal: Quantifying Slit Diaphragm Injury at Super Resolution – Nicole Endlich

Integrating Kidney Genetics into Clinical Practice ......................................................... Room 107

Moderators: Mathieu Lemaire, Jordan Nestor

2:00 p.m. Interpreting Genetic Testing and Variants of Unknown Significance – Anthony Bleyer
2:30 p.m. Making the Economic Argument for Genetic Testing to Policy Makers – Catherine Quinlan
3:00 p.m. Overview of Reverse Phenotyping in Genetic Kidney Diseases – Alexander Chang
3:30 p.m. Incorporating Genetic Testing into Clinical Practice: A Real Life Experience – Neera Dahl

New Targets in Diabetic Kidney Disease: Experimental Studies ................................. Room 120

Moderators: Farhad Danesh, Shuta Ishibe

2:00 p.m. NETosis – Berend Isermann
2:30 p.m. NADPH Oxidase – Assaad Antoine Eid
3:00 p.m. Inflammasome – Karin Jandeleit-Dahm
3:30 p.m. Advanced Glycation End Products (AGEs) and Their Precursors (Methylglyoxal [MGO]) – Nordin Hanssen

Nutrition, Metabolism, and Cardiovascular Risk in Dialysis .................. Room 114 (Nutter Theatre)

ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.

Moderators: Shweta Bansal, Marcello Tonelli

2:00 p.m. Lipids, Metabolism, and Cardiovascular Risk in Patients on Dialysis – Christoph Wanner
2:30 p.m. Peritoneal Glucose Handling and Therapeutic Strategies to Reduce Absorption – Carl Öberg
3:00 p.m. Salt, Inflammation, and Cardiac Injury in Patients on Dialysis – Christopher McIntyre
3:30 p.m. Let’s Get Moving! The Role of Exercise in Cardiovascular Health of Patients on Dialysis – Kirsten Johansen

Program is subject to change.
Thursday, November 2, 2:00 p.m. – 4:00 p.m.

Organoids with PKD: Defining What They Are and What They Can Do for Us .......... Room 105
Moderators: Jennifer Harder, Peter Igarashi

2:00 p.m. Advances, Limitations, and New Hypotheses from Organoid Modeling of Ciliopathy and ADPKD Genes – Benjamin Freedman
2:30 p.m. Organoid-on-a-Chip Model of Human ARPKD Reveals Mechanosensing – Ryuji Morizane
3:00 p.m. Organoid Model of ADPKD for Mechanism and Drug Screening – Cheng “Jack” Song
3:30 p.m. Adult Human Kidney Organoids Originate from CD24+ Cells and Can Model ADPKD – Rafael Kramann

Precision Medicine Approaches for Renal Osteodystrophy ................................................ Room 121
Moderators: Charles Ginsberg, Sharon Moe

2:00 p.m. Renal Osteodystrophy as a Heterogeneous Syndrome – Marciana Laster
2:30 p.m. Use of Bone Turnover Markers for Clinical Management of Renal Osteodystrophy – Hanne Joergensen
3:00 p.m. Novel Circulating and Noncirculating Biomarkers as Tools to Identify Renal Osteodystrophy Subgroups – Thomas Nickolas
3:30 p.m. New Approaches to Better Understand Heterogeneous Pathophysiology of Renal Osteodystrophy Subtypes – Valentin David

Selecting Kidney Donors: Challenges in Evaluating the Appropriate Candidate .......... Room 115
Moderators: Sookhyeon Park, Leonardo Riella

2:00 p.m. Living Kidney Donors with Obesity and Metabolic Syndrome: OK to Donate vs. When to Lose Weight – Sunita Singh
2:30 p.m. Prospective Kidney Donor with a Family History of Kidney Disease: When to Use Genetic Testing – Nicolae Leca
3:00 p.m. Living Kidney Donation Does Not End with the Transplant: Implementation of Long-Term Follow-Up – Aneesha Shetty
3:30 p.m. Pre- and Postdonation GFR – Emilio Poggio

Transport Mechanisms Along the Renal Tubule: Legacy of Moe Burg ......................... Room 111
Moderators: Robert Hoover, Jeff Sands

2:00 p.m. Moe Burg and His Contributions to Science – Mark Knepper
2:30 p.m. Viewing Cortical Collecting Duct Function Through Phenotype-Guided Single-Tubule Proteomics – Nina Himmerkus
3:00 p.m. New Insights into Regulatory Pathways Mediating Salt Reabsorption Regulation by Arginine Vasopressin – Maria Castañeda-Bueno
3:30 p.m. Moe Burg, the Molecular Crowding Hypothesis, and WNK Kinases – Arohan Subramanya
Thursday, November 2, 2:00 p.m. – 4:00 p.m.

**Dosing Hemodialysis: One Size Does Not Fit All,**
Including the Garabed Eknoyan, MD, Endowed Lectureship.............................................. Room 113
ASN gratefully acknowledges Wadi N. Suki, MD, for support of the Eknoyan Endowed Lectureship. ASN thanks the ASN Diabetic Kidney Disease Collaborative Task Force for assistance with this session.
Moderators: Timothy Meyer, Susan Wong
2:00 p.m.  
**Thrice Weekly Hemodialysis and Kt/Varea: Carved in Stone?** The Garabed Eknoyan, MD, Endowed Lectureship – Laura Dember
2:30 p.m.  
**Value of Residual Kidney Function: What Hemodialysis Cannot Replicate** – Tariq Shafi
3:00 p.m.  
**Incremental Hemodialysis in Patients with Residual Kidney Function: Is It Possible?**  – Mariana Murea
3:30 p.m.  
**Economic Considerations of Individualizing Hemodialysis** – Kevin Erickson

**Updates in Membranous Nephropathy: My Antigen Teacher**.............................................. Room 204
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Shane Bobart, Silke Brix
2:00 p.m.  
**Antigens in Membranous Nephropathy: A Discussion of the Clinicopathologic Features and Nomenclature** – Sanjeev Sethi
2:30 p.m.  
**Mechanisms of Injury in Glomerular Diseases** – Nicola Tomas
3:00 p.m.  
**Updates on NELL-1-Associated Membranous Nephropathy: More Discoveries and More Questions** – Tiffany Caza
3:30 p.m.  
**When to Skip the Biopsy in Membranous Nephropathy** – Paolo Cravedi

**Shovel-Ready Opportunities to Transform Kidney Transplantation in the United States**.................................................................................................................. Room 118
Moderators: Scott Bieber, Roslyn Mannon
2:00 p.m.  
**Modernizing the US Transplant Network** – Suma Nair
2:30 p.m.  
**Advancing Accountability to Better Serve Patients** – Jean Moody-Williams
3:00 p.m.  
**The Centers for Medicare and Medicaid Innovation’s Role in Improving Kidney Transplant Care** – Tom Duvall
3:30 p.m.  
**Catching Up with Modern Technology: Opportunities to Better Serve Patients in the 21st Century** – Molly McCarthy

**When the Patient Becomes the Teacher: Exploring the Intersections of Disability and Kidney Diseases**...................................................................................................... Room 119
Moderators: Amrita Mahesh, Curtis Warfield
2:00 p.m.  
**Disability 101: The ADA, Disability Identity, and Beyond** – Ken Sutha
2:30 p.m.  
**Functionality and Quality of Life: Experiences of People with Physical Disabilities** – Cynthia Delgado
3:00 p.m.  
**Leveraging Provider Personal Experience with Mental Illness in the Care of People with Kidney Diseases** – Justin Bullock
3:30 p.m.  
**Learning Through Lived Experience: Panel Discussion** – Alex Goodman

*Program is subject to change.*
Thursday, November 2, 2:00 p.m. – 4:00 p.m.

Diabetic Kidney Disease Across the Lifespan: Joint ASN-ADA Session

Moderators: Amy Mottl, Susanne Nicholas

2:00 p.m. Diabetes Management in Youth with Type 2 Diabetes – Steven Kahn
2:30 p.m. Diabetic Kidney Disease in Youth with Type 2 Diabetes: The Magnitude of the Problem – Petter Bjornstad
3:00 p.m. Apoptosis in Diabetic Kidney Disease – Andrzej Krolewski
3:30 p.m. Targeting Senescence in Diabetic Kidney Disease – LaTonya Hickson

My Patient Is Weak and Frail: What Can I Do About It?

Moderators: Matthew Abramowitz, Elizabeth Lorenz

2:00 p.m. Frailty and Physical Dysfunction in Patients with CKD: Mechanisms, Assessments, and Outcomes – Andrew Nixon
2:30 p.m. Impact of Frailty on Kidney Transplantation Outcomes – Mara McAdams-DeMarco
3:00 p.m. Therapeutic Implications of Frailty: ESKD Planning, KDIGO Guidelines, Exercise, and Beyond – Elke Schaeffner
3:30 p.m. How to Talk to Patients About Frailty – Rasheeda Hall

New Directions in Hypertension Treatment

Moderators: George Bakris, Karen Griffin

2:00 p.m. Primary Hyperaldosteronism: An Unappreciated Cause of CKD – Gordon Williams
2:30 p.m. Atrial Natriuretic Peptide: An Alternative BP-Lowering Agent – John Burnett
3:00 p.m. Angiotensinogen Knockouts and Resistant Hypertension – Akshay Desai
3:30 p.m. Aldosterone Synthetase Inhibitors as Alternatives to Spironolactone – Nancy Brown

Thursday, November 2, 4:30 p.m. – 6:00 p.m.

Liver-Kidney Connection: Time to Rethink Hepatorenal Syndrome

Moderators: Andrew Allegretti, Justin Belcher

4:30 p.m. Reliably Assessing Kidney Function in Cirrhosis: How Close Is the Light at the End of the Tunnel? – Mitra Nadim
4:50 p.m. “HepatoCardioRenal” Syndrome: Heart as the Neglected Player in HRS – Amir Kazory
5:10 p.m. When a Physical Exam Needs a Boost: The Role of POCUS in Volume Management of HRS – Abhilash Koratala
5:30 p.m. Benefits and Risks of Terlipressin Therapy in HRS – Florence Wong

Recurrent Glomerulonephritis After Kidney Transplantation

Moderators: Zahraa Hajjiri, Astrid Weins

4:30 p.m. Recurrent Membranous Nephropathy – Fernando Fervenza
4:50 p.m. Thrombotic Microangiopathies After Kidney Transplantation: Diagnosis, Prevention, and Therapy – Anthony Chang
5:10 p.m. Recurrent Primary FSGS: Can Human Kidney Organoids Be Used to Monitor Disease Activity? – Lorenzo Gallon
5:30 p.m. Recurrent IgA Nephropathy, C3 Glomerulopathy, and Membranoproliferative Glomerulonephritis – Carla Nester
Thursday, November 2, 4:30 p.m. – 6:00 p.m.

Women’s Health and the Kidneys

Room 204

In cooperation with Women in Nephrology (WIN).

Moderators: Jessica Kendrick, Andrea Oliverio

4:30 p.m.  Updates on Pathophysiology, Management, and Outcomes of Pre-Eclampsia  –  S. Ananth Karumanchi

4:50 p.m.  Hypertension in Pregnancy: Management and Long-Term Outcomes  –  Vesna Garovic

5:10 p.m.  Epidemiology and Outcomes of Pregnancy in Patients on Dialysis  –  Silvi Shah

5:30 p.m.  Abortion Laws and Kidney Diseases  –  Julie Ingelfinger

Health Care Equity in Education, Clinical Care, and Community Engagement

Room 113

ASN thanks the ASN Health Care Justice Committee for assistance with this session.

Moderators: Keith Norris, Valerie Nwanji

4:30 p.m.  Addressing Systemic Racism in Training Program Education  –  Tanjala Purnell

5:00 p.m.  Serving the Population in Need: Why Diversity in Clinical Trials Matters  –  Flor Alvarado

5:30 p.m.  Patient Advisory Boards: Engaging the Patients and Their Community to Shape Equity in Innovations  –  Vanessa Evans

Join the ScanHunt Game in the Meeting App

Scan various QR codes in the convention center and the Philadelphia Marriott Downtown to earn points. Participants with 100 or more points will be entered to win one of 3 complimentary registrations for Kidney Week 2024 in San Diego, CA.
Oral Abstract Sessions

AKI Mechanisms: Cellular and Organ Cross-Talk

Moderators: Mark de Caestecker, Michelle Starr

4:30 p.m.  **TH-OR01** Heart-Specific LIM Protein (CSRP3) as a Novel Cardiorenal Connector in Acute Cardiorenal Syndrome-Related CKD Progression – Yoshio Funahashi

4:39 p.m.  **TH-OR02** The Epidermal Growth Factor Receptor Is an Essential Mediator of Interstitial Fibrosis Development Following AKI – Shirong Cao

4:48 p.m.  **TH-OR03** Prevention of Ischemia-Reperfusion Injury (IRI)-Induced AKI by Maintaining Na+/K+ ATPase Activity – Nadezhda Zheleznova

4:57 p.m.  **TH-OR04** Analysis of the Immune Cell Landscape Identifies Immunosenescence as a Therapeutic Target in Rhabdomyolysis-Induced AKI – Snigdha Rao

5:06 p.m.  **TH-OR05** Novel Anti-Inflammatory Effects of IL-1 Receptor in Kidney Myeloid Cells Following AKI – Yanting Chen

5:15 p.m.  **TH-OR06** The Kidney-Gut-Brain Axis in AKI – Jihyun Yang

5:24 p.m.  **TH-OR07** Spatial Multi-Omic Atlas of Pyelonephritis – Xin Wang

5:33 p.m.  **TH-OR08** Differential Roles of Regnase3 in Resident Macrophages vs. Renal Tubular Epithelial Cells in Kidney Injury – Chenyu Li

5:42 p.m.  **TH-OR09** Role of YB-1 in the Early Pathogenesis of Acute Respiratory Distress Syndrome (ARDS) and Associated Renal Damage – Anna Leitz

5:51 p.m.  **TH-OR10** Injured Tubular Epithelia-Derived CCN1 Promotes the Mobilization of Fibroblasts Toward the Injury Sites at the Acute Phase After Kidney Injury – Tomohiro Nakata

CKD Mechanisms: Prediction, Propagation, and Prevention

Moderators: Mary Choi, Leslie Gewin

4:30 p.m.  **TH-OR11** Unified Cross-Species Kidney Single-Cell Atlas: Unraveling Conserved Cellular Features and Species-Specific Adaptations – Konstantin Kloetzer

4:39 p.m.  **TH-OR12** Extracellular miRNAs as Predictors of CKD Progression – Anvesha Srivastava

4:48 p.m.  **TH-OR13** Alternative Splicing in CKD – Samer Mohandes

4:57 p.m.  **TH-OR14** Adenine Accumulation Induced by Hypoxia in Kidney Organoids – Akihiro Minakawa

5:06 p.m.  **TH-OR15** Induced Senescent Cells Recruit Leukocytes and Permit Their Own Clearance from Healthy Young Kidneys – Marie Docherty

5:15 p.m.  **TH-OR16** Identification of Noninvasive Biomarkers Reflecting Cellular Mechanisms of Endothelin A (ETA) Receptor Activity and Atrasentan Response in CKD – N. Eric Olson

5:24 p.m.  **TH-OR17** LACTB Is a Kidney C Mitochondrial Metabolism – Shen Li

5:33 p.m.  **TH-OR18** Glutathione-Specific γ-Glutamylcysteine Synthetase 1 (CHAC1) Is a Kidney Disease Risk Gene by Controlling Ferroptosis – Kolligundla Prasanna

5:42 p.m.  **TH-OR19** Calprotectin Is Associated with Vascular Calcification and Cardiovascular Complications During CKD – Julie Klein

5:51 p.m.  **TH-OR20** PCSK9 Targets Megalin in the Kidney Proximal Tubule and Aggravates Proteinuria in Nephrotic Syndrome – Sandra Hummelgaard
Thursday, November 2, 4:30 p.m. – 6:00 p.m.

**Glomerular Diseases: Clinical and Translational Studies**

Moderators: Salem Almaani, Michelle O'Shaughnessy

4:30 p.m.  **TH-OR21** Prediction of Kidney Failure Using Multiple Data Domains in Glomerulonephropathy: A CureGN Study – Laura Mariani

4:39 p.m.  **TH-OR22** Plasma Metabolic Profiles and Clinical Outcomes in Focal Segmental Sclerosis (FSGS) and Minimal Change Disease (MCD) – Takaya Ozeki

4:48 p.m.  **TH-OR23** Idiopathic Collapsing Glomerulopathy Is Associated with APOL1 High-Risk Genotypes or Mendelian Variants in Most Affected Individuals in a Highly Admixed Population – Precil Neves

4:57 p.m.  **TH-OR24** Anti-Nephrin Antibody as a Potential Etiology in Primary Focal Segmental Sclerosis (FSGS) – Claire Avillach

5:06 p.m.  **TH-OR25** Exploring Epitope Spreading of PLA2R and Its Clinical Relevance in Idiopathic Membranous Nephropathy (IMN) Based on Yeast Surface Display System – Yanan Liu

5:15 p.m.  **TH-OR26** eGFR Decline in Patients with IgA Nephropathy Treated with Nefecon or Placebo: Results from the 2-Year NefiGard Phase 3 Trial – Richard Lafayette

5:24 p.m.  **TH-OR27** Safety and Efficacy of Felzartamab in Primary Membranous Nephropathy (PMN): Final Analysis of the M-PLACE Study – Brad Rovin

5:33 p.m.  **TH-OR28** Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the ADVOCATE Trial – Duvuru Geetha

5:42 p.m.  **TH-OR29** Repeat Kidney Biopsies from the AURORA 2 Study of Voclusporin in Active Lupus Nephritis – Samir Parikh

5:51 p.m.  **TH-OR30** Kidney-Related Outcomes in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of the Phase 2 NOBILITY Trial – Brad Rovin

---

**Hemodialysis Care: Quality, Vascular Access, and Emerging Threats**

Moderators: Michael Allon, Matthew Rivara

4:30 p.m.  **TH-OR41** The Relationship Between Patient Activation and Clinical Outcomes: A Longitudinal, Retrospective, Observational Study – Wael Hussein

4:39 p.m.  **TH-OR42** Self-Efficacy and Social Support Determine Self-Reported Health in Hemodialysis Patients – Krister Cromm

4:48 p.m.  **TH-OR43** Impact of Conservative Management vs. Dialysis on the Survival of US Veterans with Advanced CKD – Connie Rhee

4:57 p.m.  **TH-OR44** Encouraging a Standardized ESKD Transition Approach in a Comprehensive Kidney Care Contracting (CKCC) Program Is Associated with Increased Optimal Dialysis Starts – Roy Marcus

5:06 p.m.  **TH-OR45** Higher Patient-to-Patient Care Technician Ratios Associated with Worse Outcomes Among US In-Center Hemodialysis Patients – Laura Plantinga

5:15 p.m.  **TH-OR46** The Impact of Affordable Care Act Medicaid Expansions on Dialysis Facility Medicaid Enrollment and Quality Measures – Allison Reaves

5:24 p.m.  **TH-OR47** Roles of Matrix Metalloproteinase-2 and ETS Proto-Oncogene 1 in Rodent Arteriovenous Fistula Development – Hannah Northrup

5:33 p.m.  **TH-OR48** Long-Term Intervention Rate with Drug-Coated Balloons for Dysfunctional Arteriovenous (AV) Fistulas: Meeting KDOQI Targets in the IN.PACT AV Access Trial – Anjana Gopal

5:42 p.m.  **TH-OR49** Extreme Heat Exposure and Mortality Among Patients Receiving Dialysis – Matthew Blum

5:51 p.m.  **TH-OR50** Exposure to Wildfire-Related Particulate Matter and Risk of Hospitalization and Mortality Among Hemodialysis Patients – Hyeonjin Song
### Improving Clinical Outcomes in Diabetic Kidney Disease

**Room 121**  
**Moderators:** David Cherney, Ricardo Correa-Rotter

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.</td>
<td>TH-OR51</td>
<td>Glycated Albumin and Adverse Clinical Outcomes in Patients with CKD –</td>
<td>Mengyao Tang</td>
</tr>
<tr>
<td>4:39 p.m.</td>
<td>TH-OR52</td>
<td>Harnessing Kidney Transcriptome Profiles to Predict Rapid Progression of Diabetic Kidney Disease –</td>
<td>Dianne Acoba</td>
</tr>
<tr>
<td>4:48 p.m.</td>
<td>TH-OR53</td>
<td>FIGARO-BM, a Biomarker Study of FIGARO-DKD, Reveals New Insights into the Mode of Action of Finerenone –</td>
<td>Mario Berger</td>
</tr>
<tr>
<td>4:57 p.m.</td>
<td>TH-OR54</td>
<td>Renal Effects of Empagliflozin Alone or in Combination with Semaglutide in Albuminuric Type 2 Diabetes: A Randomized, Placebo-Controlled Trial –</td>
<td>Frederik Persson</td>
</tr>
<tr>
<td>5:06 p.m.</td>
<td>TH-OR55</td>
<td>Effects of Canagliflozin on Renal Oxygenation Evaluated Using Blood Oxygenation Level-Dependent MRI in Patients with Type 2 Diabetes –</td>
<td>Katsuhito Mori</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td>TH-OR56</td>
<td>Insulin Resistance, Kidney Outcomes, and Effects of the Endothelin Receptor Antagonist Atrasentan in Patients with Type 2 Diabetes and CKD –</td>
<td>Johannes Smeijer</td>
</tr>
<tr>
<td>5:24 p.m.</td>
<td>TH-OR57</td>
<td>Single-Nephron Dynamics in Patients with Overt Diabetic Nephropathy –</td>
<td>Akane Miura</td>
</tr>
<tr>
<td>5:33 p.m.</td>
<td>TH-OR58</td>
<td>Implementation of a Kidney Screening Intervention to Improve Early CKD Detection in Type 2 Diabetes (T2D) –</td>
<td>Margaret Spolnik</td>
</tr>
<tr>
<td>5:42 p.m.</td>
<td>TH-OR59</td>
<td>Effects of GLP-1 Receptor Agonist Dulaglutide on Profile of Circulating miRNAs Associated with ESKD in Type 2 Diabetes –</td>
<td>Eiichiro Satake</td>
</tr>
<tr>
<td>5:51 p.m.</td>
<td>TH-OR60</td>
<td>Earlier Intervention in Diabetic Kidney Disease Management Using the In Vitro Diagnostic Test PromarkerD Shows Economic Health Benefits over Current Standard of Care –</td>
<td>Kirsten Peters</td>
</tr>
</tbody>
</table>

### Investigations in Polycystic and Tubulointerstitial Kidney Diseases

**Room 105**  
**Moderators:** York Pei, Terry Watnick

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.</td>
<td>TH-OR61</td>
<td>ApoA4 Mutations Cause Autosomal Dominant Tubulointerstitial Kidney Disease with Medullary Amyloidosis –</td>
<td>Anthony Bleyer</td>
</tr>
<tr>
<td>4:39 p.m.</td>
<td>TH-OR62</td>
<td>Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Stimulates Autophagy and Restores Mitochondrial Homeostasis to Treat Uromodulin-Associated Nephropathy –</td>
<td>Chuang Li</td>
</tr>
<tr>
<td>4:48 p.m.</td>
<td>TH-OR63</td>
<td>Inactivation of Ire1alpha Endoribonuclease Domain Slows Down ADPKD in Orthologous Mouse Models –</td>
<td>Rishi Bhardwaj</td>
</tr>
<tr>
<td>4:57 p.m.</td>
<td>TH-OR64</td>
<td>Role of ER-Mitochondria Connection in the Pathogenesis of ADPKD –</td>
<td>Biswajit Padhy</td>
</tr>
<tr>
<td>5:06 p.m.</td>
<td>TH-OR65</td>
<td>Organoid Xenograft Model of Polycystic Kidney Disease Reveals Context-Dependent Cross-Talk Between Primary Cilium and Autophagy in Cystogenesis –</td>
<td>Yun Xia</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td>TH-OR66</td>
<td>Downregulation of O-GlcNAcylation, a Metabolic Regulator, Attenuates PKD Progression –</td>
<td>Matthew Kavanaugh</td>
</tr>
<tr>
<td>5:24 p.m.</td>
<td>TH-OR67</td>
<td>Ciliary Exclusion of ARL13B or Loss of Its GEF Activity for ARL3 Suppresses Polycystic Kidney Disease in Mice –</td>
<td>Robert Van Sciver</td>
</tr>
<tr>
<td>5:33 p.m.</td>
<td>TH-OR68</td>
<td>Deletion of the Circadian Clock Gene Bmal1 in Renal Collecting Ducts Leads to Rapid Cyst Growth in Autosomal Polycystic Kidney Disease –</td>
<td>Abeda Jamadar</td>
</tr>
<tr>
<td>5:42 p.m.</td>
<td>TH-OR69</td>
<td>Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease –</td>
<td>Karam Aboudehen</td>
</tr>
<tr>
<td>5:51 p.m.</td>
<td>TH-OR70</td>
<td>Aberrant Renal Microvascular Remodelling and Impaired Blood Perfusion Occur in the Early Stages of Autosomal Dominant Polycystic Kidney Disease –</td>
<td>Daniyal Jafree</td>
</tr>
</tbody>
</table>
Thursday, November 2, 4:30 p.m. – 6:00 p.m.

Mechanisms and Single-Cell Transcriptional Profiles in Transplant Rejection and Ischemia Reperfusion Injury............................................................................................................... Room 115

Moderators: Ana Konvalinka, Caroline Lamarche

4:30 p.m. TH-OR71 Live Imaging Coupled with Image-Based Machine Learning Uncovers Potential Drivers and Therapeutic Targets in a Human Model of Ischaemic Reperfusion Injury – Carmen Cusack

4:39 p.m. TH-OR72 PPARα, as a Key Determinant of Kidney Size, Revealed by Multi-Omics – Hiroaki Kikuchi

4:48 p.m. TH-OR73 Spatiotemporal Immune Atlases of Two Gene-Edited, Pig-to-Human Kidney Xenotransplants – Matthew Cheung

4:57 p.m. TH-OR74 Subpopulations of Injured Proximal Tubular Cells in Allograft Kidneys: Computational Analysis of Available scRNAseq Datasets – Sylwia da Silva Fernandes

5:06 p.m. TH-OR75 Cold Storage-Mediated p38MAPK Activation: A Potential Contributor of Proteasome Dysfunction and Kidney Damage After Transplantation – Dinesh Bhattarai

5:15 p.m. TH-OR76 Mechanism of Cold Storage-Mediated Regulation of Heat Shock Proteins in Renal Grafts After Transplantation – Seongok Lee

5:24 p.m. TH-OR77 Evaluation of Porcine Cell Chimerism and Viral Transmission Using a Preclinical Human Brain-Dead Decedent Model – Matthew Cheung

5:33 p.m. TH-OR78 The Alteration of Monocyte Subsets and the Early Acute Rejection After Kidney Transplantation – Jeongin Song

5:42 p.m. TH-OR79 MIF-CD74: A Novel Inflammatory Pathway that Suppresses Allograft-Infiltrating Tregs During Rejection – Nour Younis

5:51 p.m. TH-OR80 CER-001, a Recombinant HDL, Modulates Ischemia/Reperfusion Injury (IRI) in Hypothermic (HMP) and Normothermic Perfusion (NMP) Solutions Through pAKT/eNOS Activation – Rossana Franzin

Mechanisms of Hypertension and Cardiorenal Disease: From the Vasculature to the Gut........ Room 108

Moderators: Jennifer Pluznick, Nirupama Ramkumar

4:30 p.m. TH-OR81 Chemogenetic Activation of Pericytes Alters Systemic and Renal Hemodynamics – Jonathan Nelson

4:39 p.m. TH-OR82 Piezo1 Participates the Mechanosensation of Juxtaglomerular Cells and Regulates Renin Production In Vitro and In Vivo – Yiming Zhou

4:48 p.m. TH-OR83 Cellular-Level Transcriptomics and Three-Dimensional Imaging for Recruited Renin Cells – Hiroki Yamaguchi

4:57 p.m. TH-OR84 Identification and Characterization of a Vascular Calcification Mediator Originating in the Adrenal Glands – Shrutika Bhargava

5:06 p.m. TH-OR85 Mechanisms of Vascular Pathology Following Peritonitis in Peritoneal Dialysis Patients and Therapeutic Intervention – Esra Cetin

5:15 p.m. TH-OR86 Single-Cell Pathological Landscape Analysis of Vascular Calcification in CKD by Imaging Mass Cytometry – Yuyao Wang

5:24 p.m. TH-OR87 CKD Causes Cardiac Metabolic Remodeling via FGF23 and FGFR4 – Michaela Fuchs

5:33 p.m. TH-OR88 Left Ventricular Systolic Dysfunction in the NBCe1-B/C Knockout Mouse: A Possible Unappreciated Phenotype of Congenital Proximal Renal Tubular Acidosis (pRTA) – Clayton Brady

5:42 p.m. TH-OR89 Dopamine D4 Receptor Regulates Sodium Chloride Cotransporter in Renal Distal Convoluted Tubules – Mingzhuo Zhang

5:51 p.m. TH-OR90 Targeted Antibiotic Modulation of the Gut Microbiome Ameliorates Hypertensive Organ Damage – Moritz Wimmer

Program is subject to change.
Thursday, November 2, 4:30 p.m. – 6:00 p.m.

Onconephrology and Precision Pharmacology

Moderators: Thomas Nolin, Meghan Sise

4:30 p.m. TH-OR91 Performance of eGFR Equations for Drug Dosing in Kidney Transplant Recipients – Gregory Hundemer

4:39 p.m. TH-OR92 Performance of Creatinine and Cystatin C-Based Equations Among Patients with Hematological or Solid Cancers: Real-World Data from a Clinical Cohort – Silvia Titan

4:48 p.m. TH-OR93 MTX652, a Novel Selective USP30 Inhibitor for the Treatment of AKI: Phase 1 Results in Healthy Subjects and Model-Driven Human Efficacious Dose Projections – Pau Aceves

4:57 p.m. TH-OR94 Treatment of Diuretic Resistance with a Kappa Opioid Agonist, an Inhibitor of Central Vasopressin Secretion – Ashlyn Anderson

5:06 p.m. TH-OR95 Cystatin C-Defined AKI in Children Treated with Cisplatin – Erin Hessey

5:15 p.m. TH-OR96 SGLT2 Inhibitor Protects from Repeated Low-Dose Cisplatin-Induced Chronic Kidney Damage – Dianet Sanchez Vega

5:24 p.m. TH-OR97 Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes – Leyi Gu

5:33 p.m. TH-OR98 Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis – Thomas Mavrakanas

5:42 p.m. TH-OR99 Ondansetron and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis – Sherin Ismail

5:51 p.m. TH-OR100 Safety Outcomes of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Diabetes Mellitus and Cancer – Aisha Shaikh

Research Advances in Bone and Mineral Metabolism

Moderators: Rosa Moyses, Pablo Urena Torres

4:30 p.m. TH-OR31 PI3K/AKT/mTOR Pathway Regulates Renal Expression of Klotho – Aurora Perez-Gomez

4:39 p.m. TH-OR32 Spatial Genomics Localized Nephron Segment-Specific FGF23 and CKD Klotho-Dependent and -Independent Transcriptional Reprogramming – Lainey Hibbard

4:48 p.m. TH-OR33 Role of miR-122 on FGF23 Cleavage – Jane Thomas

4:57 p.m. TH-OR34 Direct Effects of FGF23 on Osteoblasts Contribute to Bone Defects in Dmp1KO Mice Independently of Phosphate – Dominik Kentrup

5:06 p.m. TH-OR35 The Essential Roles of miRNA and mTORC1 in Parathyroid Function and in Maintaining Parathyroid Glands in the Adult – Alia Hassan

5:15 p.m. TH-OR36 The Role of Osteopontin and Osteocyte-Derived Factors in Secondary Hyperparathyroidism-Induced Muscle Dystrophy – Eduardo Duque

5:24 p.m. TH-OR37 Bone Quality in Uremic Patients: Interactions Between Parathyroid Hormone (PTH) and Propionic Acid – Elizabeth Kermgard

5:33 p.m. TH-OR38 Calcium Isotope Ratios in Serum: A Novel Biomarker of Bone and Vessel Calcium Balance in Patients on Dialysis – Rukshana Shroff

5:42 p.m. TH-OR39 Role of Plasma Inorganic Pyrophosphate in Calciphylaxis: A Prospective Study – Api Chewcharat

5:51 p.m. TH-OR40 Loss of Renal Tubular Claudin-2 Increases Renal Calcification and Urinary Stone Disease – Muthuvel Jayachandran
<table>
<thead>
<tr>
<th>Poster Topics</th>
<th>Board #s</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDDK and Informational Posters – I</td>
<td>INFO01–INFO17</td>
</tr>
<tr>
<td>AI, Digital Health, Data Science – I</td>
<td>001–049</td>
</tr>
<tr>
<td>AKI: Liver Disease, Nephrotoxicity, Novel Therapeutics</td>
<td>050–078</td>
</tr>
<tr>
<td>AKI: Mechanisms – I</td>
<td>079–126</td>
</tr>
<tr>
<td>Bone and Mineral Metabolism: CKD-MBD Updates</td>
<td>127–165</td>
</tr>
<tr>
<td>Diabetic Kidney Disease: Clinical – I</td>
<td>166–194</td>
</tr>
<tr>
<td>Hypertension and CVD: Clinical – I</td>
<td>195–244</td>
</tr>
<tr>
<td>Hemodialysis: Volume, Metabolic Complications, Clinical Outcomes</td>
<td>245–304</td>
</tr>
<tr>
<td>Home Dialysis – I</td>
<td>305–354</td>
</tr>
<tr>
<td>Fluid, Electrolyte, Acid-Base Disorders: Clinical – I</td>
<td>355–400</td>
</tr>
<tr>
<td>Genetic Diseases: Cystic - Therapeutic Investigations and Prognosis</td>
<td>401–445</td>
</tr>
<tr>
<td>Genetic Diseases: Glomerulopathies – I</td>
<td>446–487</td>
</tr>
<tr>
<td>Pediatric Nephrology – I</td>
<td>488–529</td>
</tr>
<tr>
<td>Glomerular Diseases: From Inflammation to Fibrosis – I</td>
<td>530–579</td>
</tr>
<tr>
<td>Glomerular Diseases: Clinical and Epidemiologic Studies</td>
<td>580–636</td>
</tr>
<tr>
<td>Glomerular Diseases: Epidemiology and Case Reports</td>
<td>637–691</td>
</tr>
<tr>
<td>Glomerular Diseases: Case Reports</td>
<td>692–732</td>
</tr>
<tr>
<td>Glomerular Diseases: Podocyte Biology – I</td>
<td>733–791</td>
</tr>
<tr>
<td>Pathology and Lab Medicine – I</td>
<td>792–819</td>
</tr>
<tr>
<td>Transplantation: Clinical – I</td>
<td>820–869</td>
</tr>
<tr>
<td>Transplantation: Donation and Access</td>
<td>870–911</td>
</tr>
<tr>
<td>Health Maintenance, Nutrition, Metabolism – I</td>
<td>912–945</td>
</tr>
<tr>
<td>Anemia in CKD: Risk Factors, Practice Patterns, Therapies</td>
<td>946–988</td>
</tr>
<tr>
<td>CKD Epidemiology, Risk Factors, Prevention – I</td>
<td>989–1031</td>
</tr>
<tr>
<td>CKD Progression and Complications: Diagnosis, Prognosis, Risk Factors</td>
<td>1032–1087</td>
</tr>
<tr>
<td>COVID-19 – I</td>
<td>1088–1112</td>
</tr>
<tr>
<td>Late-Breaking Clinical Trials</td>
<td>1113–TBD</td>
</tr>
</tbody>
</table>

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.

Welcome Reception
Thursday, November 2
6:00–7:00 p.m.
Exhibit Hall C

The Welcome Reception is supported by

Program is subject to change.
DIGITAL PATHOLOGY ROOM
ROOM 110

You are invited to a hands-on review session of all the digital slides from the Renal Biopsy: Clinical Correlations session vignettes prior to Saturday, November 4, when the final diagnoses are discussed in-depth and answers to the cases are distributed. Biopsy materials are available with renal pathologists onsite to direct your study of the cases and to provide individual instruction. There is no fee to visit the Pathology Room; however, space is limited and available on a first-come, first-served basis.

Thursday
November 2
9:30 a.m. — 4:30 p.m.

Friday
November 3
9:30 a.m. — 4:30 p.m.

ASN thanks the Renal Pathology Society for assistance with the Renal Biopsy session and the Digital Pathology Room.

The Digital Pathology Room is supported by NOVARTIS
DAY-AT-A-GLANCE
Friday, November 3

6:45 a.m. – 7:45 a.m.
Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)
Doors open at 6:30 a.m.
Radiofrequency Renal Denervation: The Next Frontier for Difficult-to-Control Hypertension........ Salon I
Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases................................................................................................. Salon D

8:00 a.m. – 9:30 a.m.
Plenary: Peters Award, Seldin Award and Address, State-of-the-Art Lecture................................. Hall A

9:30 a.m. – 2:30 p.m.
Morning Break (9:30 a.m. – 10:00 a.m.) ......................................................................................... Exhibit Hall C
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.) ................................................................. Exhibit Hall C
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.) ................................................................. Exhibit Hall C

10:00 a.m. – 1:45 p.m.
Exhibitor Spotlights ................................................................................................................................. Exhibit Hall C
Please see pages 10-11 for the schedule and topics.

10:30 a.m. – 12:30 p.m.
Clinical Practice Sessions
Calming the Waters: Managing Hyponatremia in Different Clinical Settings............................... Room 103
Climbing Up and Down the AKI Mountain: Navigating Data, Divides, Diagnostics, and Dialysis................................................................. Room 201
Clinical Stone Disease: Tools and Risk Factors, with the Coburn Endowed Lectureship ........... Room 119
Home Dialysis Quiz and Questionnaire................................................................................................. Room 113
Implementation of Novel AKI Biomarkers in Clinical Practice ........................................................ Ballroom B
Leave No Kidney Behind: Optimizing Utilization of Deceased and Living Donor Kidneys........ Room 115
New Insights into Achieving Meaningful Weight Loss in CKD, with the Rose Endowed Lectureship.......................................................................................................................... Room 108

Translational Sessions
Collagen IV Conundrums: Genetic Variants and Clinical Management ........................................... Room 204
Heart-Kidney Cross-Talk: How Should I Be Approaching Cardiorenal Disease?......................... Ballroom A
Insights into Liver-Kidney Cross-Talk...................................................................................................... Room 118

Oral Abstract Session
High-Impact Clinical Trials: Part 1........................................................................................................ Hall A

Other Events
Advancing Health Equity for All: Addressing SDoH in Access to Transplant..................................... Room 109
Fellows-in-Training Bowl: Semi-Finals and Finals .............................................................................. Exhibit Hall C

12:45 p.m. – 1:45 p.m.
Educational Symposia (Philadelphia Marriott Downtown Level 5, Grand Ballroom)
Doors open at 12:30 p.m.
Caring for the Patient with AKI in Cirrhosis: New Tools and Opportunities............................... Salon L
Hyperkalemia in Diabetes and Heart Failure: Optimizing Management to Mitigate Risk .......... Salon I
IgA Nephropathy: Proteinuria, Vasoactive Peptides, and the Evolving Treatment Landscape .......Salon A
What’s Complement Got to Do with It? ANCA Vasculitis and the Complement System.............. Salon D
### 1:00 p.m. – 2:00 p.m.
Top Trainee Posters.................................................................................................................. Exhibit Hall C

### 2:00 p.m. – 4:00 p.m.

#### Basic/Clinical Science Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Bioenergetics of Diabetic Kidneys, with the Brenner Endowed Lectureship</td>
<td>Room 120</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Carving New Paths for AKI Therapy: What’s on the Horizon</td>
<td>Room 108</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Cilia Proteins in Development and Diseases</td>
<td>Room 107</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Higher and Higher Resolution: Advances in Single-Cell or -Omis Studies in CKD</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Innovative Immunosuppression and Monitoring Strategies in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pediatric Kidney Transplantation</td>
<td>Room 105</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Microvascular Inflammation in Kidney Transplantation: An Unresolved Dilemma</td>
<td>Room 109</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Pragmatic Clinical Trials as Means to Update Clinical Practice in CKD-MBD</td>
<td>Room 119</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Translation of Genetic Discoveries in Nephrotic Syndrome,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>with the Winn Endowed Lectureship</td>
<td>Room 204</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Water Channels in the Kidneys and Beyond</td>
<td>Room 111</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Xenotransplantation Is on the Horizon</td>
<td>Room 115</td>
</tr>
</tbody>
</table>

#### Clinical Practice Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Case Studies in Glomerular Diseases 2023</td>
<td>Ballroom B</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Environmental Health and the Kidneys</td>
<td>Room 114</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Managing Patients on Dialysis: How Can We Improve Care?</td>
<td>Room 113</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Nephrocardiology Care Models: From Idea to Implementation</td>
<td>Room 118</td>
</tr>
</tbody>
</table>

#### Translational Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Future of Data Science in Kidney Medicine and Research</td>
<td>Room 103</td>
</tr>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Onconephrology: Focus on Hematology</td>
<td>Room 201</td>
</tr>
</tbody>
</table>

#### Special Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:00 p.m. – 4:00 p.m.</td>
<td>Winning Team: The Nephrology Workforce for the 21st Century</td>
<td>Room 121</td>
</tr>
</tbody>
</table>

### 4:00 p.m. – 4:30 p.m.

#### Afternoon Break

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 p.m. – 4:30 p.m.</td>
<td>Foyers of Rooms 201/204, 108, 118</td>
</tr>
</tbody>
</table>

### 4:30 p.m. – 6:00 p.m.

#### Clinical Practice Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Controversies in C3 Glomerulopathy</td>
<td>Room 201</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Drug Dosing in Advanced CKD and ESKD</td>
<td>Room 113</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Serving the Underserved: Improving Kidney Health in Underserved Populations</td>
<td>Room 204</td>
</tr>
</tbody>
</table>

#### Translational Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Dietary and Metabolic Interventions in ADPKD:</td>
<td>Room 114</td>
</tr>
<tr>
<td></td>
<td>The Rationale and Clinical Benefit</td>
<td>(Nutter Theatre)</td>
</tr>
</tbody>
</table>

#### Oral Abstract Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>AKI Prediction and Assessment: Traditional and Novel Tools</td>
<td>Room 118</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Development, Organoids, and Genetic Models of Kidney Diseases</td>
<td>Room 105</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Fluid, Electrolyte, and Acid-Base Disorders: Basic Research</td>
<td>Room 111</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>How Sweet It Is: Basics of Diabetic Kidney Disease</td>
<td>Room 121</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Interventions to Reduce CKD Progression</td>
<td>Room 119</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Kidney Pathology: From Classic Clinicopathologic Studies to Computational Pathology</td>
<td>Room 109</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Kidney Transplantation: Biomarkers, New and Old.</td>
<td>Room 115</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Managing the Many Facets of Home Dialysis</td>
<td>Room 120</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Navigating a Path to Diversity and Equity in Kidney Health</td>
<td>Room 107</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Novel Clinical Impacts on Cardiorenal Disease</td>
<td>Room 103</td>
</tr>
<tr>
<td>4:30 p.m. – 6:00 p.m.</td>
<td>Podocytopathy: Novel Insights and Emerging Therapeutic Targets</td>
<td>Room 108</td>
</tr>
</tbody>
</table>
Friday, November 3, 6:45 a.m. – 7:45 a.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)
Doors open at 6:30 a.m. Breakfast is provided.
Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Radiofrequency Renal Denervation: The Next Frontier for Difficult-to-Control Hypertension .............................................................. Salon I
Support is provided by an educational grant from Medtronic.

6:45 a.m.  Introduction – Jennifer Pollock (Moderator)
6:55 a.m.  Interpreting the Renal Denervation Literature: Mechanisms, Safety, and Effectiveness – Raymond Townsend
7:15 a.m.  Practical Approaches to Renal Denervation: Establishing a Program and Optimizing Patient Selection – Michael Weber
7:35 a.m.  Questions and Answers

Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases.................................................. Salon D
Support is provided by an educational grant from Novartis Pharmaceuticals Corporation.

6:45 a.m.  Introduction – Duvuru Geetha (Moderator)
6:55 a.m.  Complement-Mediated Kidney Diseases: Novel Insights and New Possibilities – Andrew Bomback
7:15 a.m.  New Horizons: Considering the Evolving Therapeutic Landscape for IgA Nephropathy – Chee Kay Cheung
7:35 a.m.  Questions and Answers

Friday, November 3, 8:00 a.m. – 9:30 a.m.

Plenary.................................................................................................................. Hall A
The Donald W. Seldin Young Investigator Award is cosponsored by ASN and the American Heart Association Council on the Kidney in Cardiovascular Disease.

8:10 a.m.  John P. Peters Award – Katherine Tuttle
8:20 a.m.  Donald W. Seldin Young Investigator Award and Address “Human Kidney Organoids for Disease Modeling and Regeneration” – Benjamin Freedman
8:50 a.m.  State-of-the-Art Lecture “How Do You Feel? The Molecules that Sense Touch” – Ardem Patapoutian

Friday, November 3, 10:30 a.m. – 12:30 p.m.

Calming the Waters: Managing Hyponatremia in Different Clinical Settings .............. Room 103
Moderators: Roger Rodby, Amy Yau
10:30 a.m.  Patients with Severe Hyponatremia in the Intensive Care Unit – Helbert Rondon Berrios
11:00 a.m.  Patients with Chronic SIAD in the Office – Annabelle Warren
11:30 a.m.  Patients with Cirrhosis and Hyponatremia – Juan Carlos Velez
12:00 p.m.  Patients with Heart Failure and Hyponatremia – Frederik Verbrugge

Program is subject to change.
Climbing Up and Down the AKI Mountain: Navigating Data, Divides, Diagnostics, and Dialysis ................................................................................................................................. Room 201
ASN thanks the ASN AKINow Recovery/Post-AKI Workgroup and Public Awareness and Education Workgroup for assistance with this session.
Support is provided by an educational grant from 3iveLabs.
Moderators: Anitha Vijayan, Ron Wald
Patient Commentator: Marla Levy
10:30 a.m.  Raising Awareness: Impact of AKI on Outcomes – Michael Heung
11:00 a.m.  Bridging the Divide from Hospital to Home: Challenges and Opportunities – Edward Siew
11:30 a.m.  Another Urinary Biomarker for AKI? A Discussion of CCL14 – Melanie Meersch
12:00 p.m.  Set Them Free: How to Liberate AKI-D Survivors – Chi-yuan Hsu

Clinical Stone Disease: Tools and Risk Factors, Including the Jack W. Coburn, MD, Endowed Lectureship ................................................................. Room 119
ASN gratefully acknowledges Amgen for support of the Coburn Endowed Lectureship.
Moderators: Sonia Fargue, Alan Pao
10:30 a.m.  Who Is at Risk for Recurrent Stone Disease? – Pietro Manuel Ferraro
11:00 a.m.  Stone Prevention in Patients with Bowel Disease: The Jack W. Coburn, MD, Endowed Lectureship – Elaine Worcester
11:30 a.m.  Nephrolithiasis in Kidney Transplantation – Mira Keddis
12:00 p.m.  A (Warming) World in a Grain of Sand: Impact of Societal and Environmental Change on Stone Risk – David Goldfarb

Home Dialysis Quiz and Questionnaire .................................................................................. Room 113
ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.
Moderators: Joel Glickman, Rajnish Mehrotra
10:30 a.m.  Clinical Advantages of More Frequent Dialysis – Eric Weinhandl
11:00 a.m.  The Right Balance: Individualizing Peritoneal Dialysis Prescriptions – Jeffrey Perl
11:30 a.m.  Getting Creative: Finding the Right Prescription for Home Hemodialysis – Brigitte Schiller
12:00 p.m.  Hot and SPICEy: Antimicrobial Resistance in Peritoneal Dialysis Infections from Prevention to Treatment – Sharon Nessim

Implementation of Novel AKI Biomarkers in Clinical Practice ............................................ Ballroom B
Moderators: Rajit Basu, Blaithin McMahon
10:30 a.m.  How to Use Advanced Test Systems (TIMP2-IGFBP7) Testing in Clinical Practice – Jay Koyner
11:00 a.m.  How to Use Neutrophil Gelatinase-Associated Lipocalin (NGAL) Testing in Clinical Practice – Jean Maxime Cote
11:30 a.m.  How to Use Functional AKI Biomarkers in Clinical Practice – Marlies Ostermann
12:00 p.m.  How to Use Biomarkers of Drug-Induced Kidney Injury in Clinical Drug Development – Vishal Vaidya
Friday, November 3, 10:30 a.m. – 12:30 p.m.

Leave No Kidney Behind: Optimizing Utilization of Deceased and Living Donor Kidneys ................................................................. Room 115
ASN thanks the ASN Diversity, Equity, and Inclusion Committee for assistance with this session.
Moderators: Vineeta Kumar, Adetokunbo Taiwo
10:30 a.m. Reflections of a Two-Time Kidney Transplant Recipient – Nichole Jefferson
11:00 a.m. Shared Decision Making in Deceased Donor Kidney Allocation – Sumit Mohan
11:30 a.m. A Living Kidney Donor’s Experience: Barriers and Opportunities – Martha Gershun
12:00 p.m. Engaging Friends and Families to Enhance Living Donor Kidney Transplant Among African Americans – L. Ebony Boulware

New Insights into Achieving Meaningful Weight Loss in CKD, Including the Burton D. Rose, MD, Endowed Lectureship ........................... Room 108
ASN gratefully acknowledges Wolters Kluwer (publisher of UpToDate), the Beth Israel Deaconess Medical Center Department of Medicine Foundation, the Rose Family, and several of Dr. Rose’s colleagues for supporting this lectureship.
Moderators: Allon Friedman, Sarah Schrauben
10:30 a.m. Hypobaric Hypoxia and Its Cardiorenal Benefit for Weight Loss: The Burton D. Rose, MD, Endowed Lectureship – Biff Palmer
11:00 a.m. Ketogenic Metabolic Therapies for CKD – Johannes Kovarik
11:30 a.m. Bariatric Surgery: Mechanism and Efficacy in CKD – Aleksandra Kukla
12:00 p.m. Pharmacologic Mechanisms of Weight Loss to Include SGLT2 Inhibitors and GLP1/GIP Agonists – Alexander Chang

Heart-Kidney Cross-Talk: How Should I Be Approaching Cardiorenal Disease? .......... Ballroom A
Moderators: Mark Sarnak, Wolfgang Winkelmayer
10:30 a.m. Kidney Biomarkers to Guide Diuresis in Patients with Acute Decompensated Heart Failure – Jeffrey Testani
11:00 a.m. Implementation of a New Era of Goal-Directed Medical Therapy for Patients with Cardiorenal Disease – Katherine Tuttle
11:30 a.m. Direct Oral Anticoagulants in Patients Treated with Dialysis: Where Are We Now? – Glenn Chertow
12:00 p.m. How Should We Screen for CVD in Patients with CKD? – David Charytan

Insights into Liver-Kidney Cross-Talk .................................................................................................................. Room 118
Moderators: Beom Seok Kim, Ashita Tolwani
10:30 a.m. Liver-Kidney Connection in Chronic Liver Disease – Florence Wong
11:00 a.m. Non-Alcoholic Fatty Liver Disease as a Driver of CKD – Mazen Noureddin
11:30 a.m. Liver Biomarkers and Kidney Outcomes – Chan-Young Jung
12:00 p.m. CKD in Liver Transplant Recipients – Maria Ajaimy

Program is subject to change.
Friday, November 3, 10:30 a.m. – 12:30 p.m.

**High-Impact Clinical Trials: Part 1** ................................................................. Hall A
Please check the Kidney Week app or the ASN website for session details.

**Advancing Health Equity for All: Addressing SDoH in Access to Transplant** .......... Room 109
Note: Continuing education credits are not being offered for this activity.

**Fellows-in-Training Bowl: Semi-Finals and Finals** ................................. Futures Theater - Exhibit Hall C
Support is provided by Calliditas Therapeutics.
Note: Continuing education credits are not being offered for this activity.

---

Friday, November 3, 12:45 p.m. – 1:45 p.m.

**Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)**
Doors open at 12:30 p.m. Lunch is provided.
Limited seating; first-come, first-served to fully paid Annual Meeting participants.

**Caring for the Patient with AKI in Cirrhosis: New Tools and Opportunities** ........ Salon L
Support is provided by an educational grant from Mallinckrodt Pharmaceuticals.
12:45 p.m.  Introduction – Andrew Davenport (Moderator)
12:55 p.m.  Diagnosing and Monitoring HRS-AKI: Present and Future – Luis Juncos
1:15 p.m.  How Hepatologists Think About HRS-AKI Treatment in 2023 – Guadalupe Garcia-Tsao
1:35 p.m.  Questions and Answers

**Hyperkalemia in Diabetes and Heart Failure: Optimizing Management to Mitigate Risk** .... Salon I
Support is provided by an educational grant from AstraZeneca.
12:45 p.m.  Introduction – Joanna Hudson (Moderator)
12:55 p.m.  Hyperkalemia in the Patient with Diabetic Kidney Disease – David Mount
1:15 p.m.  Hyperkalemia in the Patient with Heart Failure – Angela Yee Moon Wang
1:35 p.m.  Questions and Answers

**IgA Nephropathy: Proteinuria, Vasoactive Peptides, and the Evolving Treatment Landscape** ................................................................. Salon A
Support is provided by an educational grant from Travere Therapeutics, Inc.
12:45 p.m.  Introduction – Daniel Cattran (Moderator)
12:55 p.m.  Endothelin-1 Effects on Glomerular Filtration, Kidney Inflammation, and Damage – Carmen De Miguel
1:15 p.m.  Emerging Therapeutic Options in IgA Nephropathy – Pietro Canetta
1:35 p.m.  Questions and Answers

**What’s Complement Got to Do with It? ANCA Vasculitis and the Complement System** .... Salon D
This activity is supported by educational funding provided by Amgen.
12:45 p.m.  Introduction – Ladan Zand (Moderator)
12:55 p.m.  The Pathophysiology of ANCA Vasculitis and the Role of Complement – Adrian Schreiber
1:15 p.m.  Treatment and Management of ANCA Vasculitis – Michael Walsh
1:35 p.m.  Questions and Answers
Bioenergetics of Diabetic Kidneys, Including the Barry M. Brenner, MD, Endowed Lectureship

**Room 120**

ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Brenner Endowed Lectureship.

Moderators: Luigi Gnudi, Krisztian Stadler

2:00 p.m. **Toward Solutions! Pro-Resolving Lipid Mediators of Metabolism and Inflammation: The Barry M. Brenner, MD, Endowed Lectureship** – Catherine Godson

2:30 p.m. **Mitochondria and Sterile Inflammation in Diabetic Kidney Disease** – Sandra Merscher

3:00 p.m. **Mitochondrial Enzymes, Like PKM2, Offering Protection Against Diabetic Kidney Disease** – George King

3:30 p.m. **Mitochondrial Targets in Diabetic Kidney Disease** – Melinda Coughlan

**Carving New Paths for AKI Therapy: What’s on the Horizon**

**Room 108**

Moderators: Neil Hukriede, Motoko Yanagita

2:00 p.m. **Controlling Cell Death** – Andreas Linkermann

2:30 p.m. **AKI and Krüppel-Like Transcription Factors** – Sian Piret

3:00 p.m. **Endothelial Hypoxic Metabolic Reprogramming in Kidney Injury and Repair** – Pinelopi Kapitsinou

3:30 p.m. **Non-Coding RNA in AKI** – Laura Denby

**Cilia Proteins in Development and Diseases**

**Room 107**

Moderators: Moe Mahjoub, Robin Maser

2:00 p.m. **Visualizing Cilia Function in Kidney Injury and Diseases** – Bradley Yoder

2:30 p.m. **Extracellular Protease Modulation of the Cilium Transition Zone in Kidney Development and Diseases** – Sumeda Nandadasa

3:00 p.m. **Polycystin-1’s C-Terminal Tail Suppresses Cystic Disease** – Michael Caplan

3:30 p.m. **Ciliary Disease and Potential Therapeutic Mechanisms** – Sophie Saunier

**Higher and Higher Resolution: Advances in Single-Cell or -Omics Studies in CKD**

**Ballroom A**

Moderators: Hiroki Kobayashi, Marcus Pezzolesi

2:00 p.m. **Single-Cell Modalities** – Parker Wilson

2:30 p.m. **Epigenetics in CKD** – Kaori Hayashi

3:00 p.m. **Tissue Proteome of the Diabetic Kidneys** – Daigoro Hirohama

3:30 p.m. **Circulating Proteomics and Protein Biomarkers of Diabetic Kidney Disease** – Ruth Dubin

**Innovative Immunosuppression and Monitoring Strategies in Pediatric Kidney Transplantation**

**Room 105**

Moderators: Sandra Amaral, Rachel Engen

2:00 p.m. **Past, Present, and Future of Immunosuppression in Pediatric Kidney Transplantation** – Eileen Chambers

2:30 p.m. **Novel Desensitization and Treatment Strategies for Antibody-Mediated Rejection in Children** – Dechu Puliyanda

3:00 p.m. **Is HLA Eplet Matching a Viable Way to Improve Clinical Outcomes in Pediatric Kidney Transplantation?** – Anat Tambur

3:30 p.m. **Costimulation Blockade in Pediatric Kidney Transplantation: The ADVANTAGE Trial** – David Briscoe

---

Program is subject to change.
Microvascular Inflammation in Kidney Transplantation: An Unresolved Dilemma.......... Room 109
ASN thanks the Renal Pathology Society for assistance with this session.
Moderators: Surya Seshan, Kristen Tomaszewski

2:00 p.m. Mechanisms of Microvascular Inflammation in the Kidney Allograft – Dany Anglicheau
2:30 p.m. Clinical Significance of Microvascular Inflammation: Are Donor-Specific Antibodies Required? – Chul Woo Yang
3:00 p.m. Gene Expression Profiling in Microvascular Inflammation – Ivy Rosales
3:30 p.m. Pathologic Scoring of Microvascular Inflammation: Importance in Diagnosis and Prognosis in Antibody-Mediated Rejection – Mark Haas

Pragmatic Clinical Trials as Means to Update Clinical Practice in CKD-MBD ................. Room 119
Moderators: Orlando Gutierrez, Michal Melamed

2:00 p.m. Overview of Prior Pragmatic Clinical Trials in Dialysis and Applications to CKD-MBD – Andrea Cowan
2:30 p.m. Overview of the HiLo Trial – Daniel Edmonston
3:00 p.m. Overview of the PHOSPHATE Trial – Ron Wald
3:30 p.m. Rationale for a Pragmatic Clinical Trial for Management of Secondary Hyperparathyroidism – Julia Scialla

Translation of Genetic Discoveries in Nephrotic Syndrome,
Including the Michelle P. Winn, MD, Endowed Lectureship ................. Room 204
ASN gratefully acknowledges Duke University School of Medicine, the school’s Division of Nephrology, and several individuals for support of the Winn Endowed Lectureship.
Session support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Gentzon Hall, Daria Ilatovskaya

2:00 p.m. Illuminating the Genetics of Nephrotic Syndrome – Krzysztof Kiryluk
2:30 p.m. MUC’ing Things Up: Exploring MUC1 as a Therapeutic Target in Proteinuric Kidney Disease – Anna Greka
3:00 p.m. Podocyte Lipid Handling as a Therapeutic Target for Collagenopathy: The Michelle P. Winn, MD, Endowed Lectureship – Alessia Fornoni
3:30 p.m. Emerging Therapeutics for COVID-19-Associated Nephropathy (COVAN) and HIV-Associated Nephropathy (HIVAN) in Patients with APOL1 Renal Risk Variants – Opeyemi Olabisi

Water Channels in the Kidneys and Beyond ......................................................................... Room 111
Moderators: James McCormick, Cesar Romero

2:00 p.m. YAP1 Controls the Expression of Collecting Duct Aquaporins and Water Homeostasis – Yin Xia
2:30 p.m. AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis – Olivier Devuyst
3:00 p.m. Ribosomal S6 Kinase (RSK): A New Player in the Regulation of AQP2 Intracellular Trafficking – Pui Susan Cheung
3:30 p.m. Estrogen Regulates Aquaporin-2 in the Kidneys – Rikke Norregaard
Xenotransplantation Is on the Horizon ................................................................. Room 115
Moderators: Reza Abdi, Xun-Rong Luo
2:00 p.m. First Pig to Human Cardiac Xenotransplantation: A Success? –
Muhammad Mohiuddin
2:30 p.m. First Pig to Human Kidney Xenotransplantation – Jayme Locke
3:00 p.m. Progress in Kidney Xenotransplantation: Are We Ready for Clinics? –
Andrew Adams
3:30 p.m. Scientific Approaches That Address Compatibility and Immunosuppression for
Xenotransplanted Kidneys – David Cooper

Case Studies in Glomerular Diseases 2023 ..................................................... Ballroom B
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Ingeborg Bajema, Brad Rovin
2:00 p.m. Case 1 – Kirk Campbell
2:30 p.m. Case 2 – Katherine Dell
3:00 p.m. Case 3 – Koyal Jain
3:30 p.m. Case 4 – Arvind Nagra

Environmental Health and the Kidneys.................................................. Room 114 (Nutter Theatre)
Moderators: Jason Watts, Daniel Weiner
2:00 p.m. Emergency Preparedness in Nephrology Care – Myra Kleinpeter
2:30 p.m. Climate Change: What to Know as a Nephrologist – Sarah Young
3:00 p.m. Kidney Health in Agricultural Workers – Marc De Broe
3:30 p.m. Use of Water in Dialysis and Its Impact on the Environment – Suzanne Watnick

Managing Patients on Dialysis: How Can We Improve Care? ......................... Room 113
Moderators: Rebecca Schmidt, Carmine Zoccali
2:00 p.m. Potential Hemodialysis Ultrafiltration Rate Warning Levels: How Best to Scale
These to Body Size – John Daugirdas
2:30 p.m. Keys to Success in Managing Vascular Access in Dialysis Patients –
Vandana Niyyar
3:00 p.m. Vaccinations in the Dialysis Unit: Integrating the Patient Perspective into
Processes and Practice – Liz McNamara
3:30 p.m. Uremic Pruritus: Recent Advances in Management – Tariq Shafi

Nephrocardiology Care Models: From Idea to Implementation ....................... Room 118
Moderators: Vivek Bhalla, Janani Rangaswami
2:00 p.m. Pragmatic Approaches of Building a Nephrocardiology Service in the United
States – Jacob Stevens
2:30 p.m. Innovations in Clinical Care, Education, and Research through
Nephrocardiology Subspecialization: A Nephrology Perspective – Nisha Bansal
3:00 p.m. Nephrocardiology Services as a Path to Improving Patient Outcomes:
A Cardiology Perspective – Conrad Macon
3:30 p.m. International Perspectives and Opportunities to Build Cardionephrology
Subspecialization – Liam Plant

Program is subject to change.
Winning Team: The Nephrology Workforce for the 21st Century

Friday, November 3, 2:00 p.m. – 4:00 p.m.

Winning Team: The Nephrology Workforce for the 21st Century

Room 121
Moderators: Jane Davis, Mitchell Rosner

2:00 p.m. Advanced Practice Providers’ Role in Nephrology in 2023 – Kim Zuber
2:30 p.m. Advocacy and Policy: What Can Nephrologists and National Organizations Do? – Carmen Cervantes
3:00 p.m. Current Landscape and Needs of the Nephrology Workforce – Eleanor Lederer
3:30 p.m. Mentoring the Next Generation of Nephrologists – Samira Farouk

Future of Data Science in Kidney Medicine and Research

Room 103
Moderators: Meredith McAdams, Shina Menon

2:00 p.m. AI Today and Tomorrow in Medicine – Karandeep Singh
2:30 p.m. Finding and Defining Kidney Phenotypes in the Electronic Health Record – Adriana Hung
3:00 p.m. Coding in Data Science: Addressing Issues of Transparency, Reproducibility, and Public Availability – Girish Nadkarni
3:30 p.m. The “Nudge” in Clinical Practice: Aligning Patients and Providers for Data-Driven Medicine – M. Kit Delgado

Onconephrology: Focus on Hematology

Room 201
Moderators: Ala Abudayyeh, Claude Bassil

2:00 p.m. Thrombotic Microangiopathy: Drugs and Cancer – Nelson Leung
2:30 p.m. Renal Complications from Lymphomas and Leukemia: Indolent or Aggressive – Anushree Shirali
3:00 p.m. Light Chain-Related Kidney Injury: Light Chain Tubulopathy and Cast Nephropathy – Sheron Latcha
3:30 p.m. Kidney Involvement from AL Amyloidosis: Diagnosis and Treatment – Priya Deshpande

Controversies in C3 Glomerulopathy

ASN thanks the European Renal Association (ERA) and ERA Ambassador, Dr. Hans Anders.
Session support is provided by an educational grant from Travere Therapeutics, Inc.

Room 201
Moderators: Joshua Thurman, Marina Vivarelli

4:30 p.m. What Is C3 Glomerulopathy and What Is It Not? – Andrew Bomback
4:50 p.m. Drivers of C3 Glomerulopathy – Hans Anders
5:10 p.m. Role of Biomarkers in C3 Glomerulopathy – Veronique Fremeaux Bacchi
5:30 p.m. Standard Immune Suppression and Targeted Therapeutics in C3 Glomerulopathy – Carla Nester

Drug Dosing in Advanced CKD and ESKD

Room 113
Moderators: Swapnil Hiremath, Talat Alp Ikizler

4:30 p.m. Drug Dosing in Kidney Diseases and Dialysis: Factors That Affect Drug Clearance – Linda Awdishu
4:50 p.m. Thiazide Diuretics in Advanced CKD and Dialysis: Are They Effective? – Rajiv Agarwal
5:10 p.m. Remnant Kidneys Can Still Secrete: Implications on Drug Dosing – Catherine Yeung
5:30 p.m. KDIGO Guidelines: Prescribing and Deprescribing Drugs in CKD – Rasheeda Hall
Friday, November 3, 4:30 p.m. – 6:00 p.m.

Serving the Underserved: Improving Kidney Health in Underserved Populations........ Room 204
Moderators: Flor Alvarado, Kalani Raphael
4:30 p.m. Kidney Diseases in Incarcerated Populations – Laura Maursetter
4:50 p.m. Relationship Between CKD and Psychiatric Illness – Clodagh Cogley
5:10 p.m. Understanding the Burden and Risk of Kidney Diseases in Asian-American Populations – Leslie Wong
5:30 p.m. Culture-Centered Approaches to Reducing Health Disparities in Indigenous Populations – Vallabh Shah

Dietary and Metabolic Interventions in ADPKD:
The Rationale and Clinical Benefit ......................................................... Room 114 (Nutter Theatre)
Moderators: Meyeon Park, Ronald Perrone
4:30 p.m. Biological Basis for Metabolic Treatment of ADPKD: Increased Aerobic Glycolysis (Warburg Effect) – Maria Irazabal
4:50 p.m. Dietary Protein, Immune Cells, and ADPKD Progression – Takamitsu Saigusa
5:10 p.m. Ketogenic Diet and ADPKD – Roman-Ulrich Mueller
5:30 p.m. Targeting Adiposity and Caloric Restriction in ADPKD – Kristen Nowak

Oral Abstract Sessions

AKI Prediction and Assessment: Traditional and Novel Tools ......................................................... Room 118
Moderators: Rolando Claure-Del Granado, Etienne Macedo
4:30 p.m. FR-OR01 AKI Is Associated with Long-Term Decline in Cognitive Function at 3 Years: ASSESS-AKI Study – Pavan Bhatraju
4:39 p.m. FR-OR02 AKI, Glomerulonephritis, and Tubulointerstitial Nephritis Following Vaccination: VigiBase Analysis – Soo-Young Yoon
4:48 p.m. FR-OR03 Use of a Recurrent Neural Network to Predict Development of Nephrotoxic AKI in Adults – Benjamin Griffin
4:57 p.m. FR-OR04 Genome-Wide Association Study of Hospitalized AKI – Edward Siew
5:06 p.m. FR-OR05 Machine Learning-Guided Novel Subphenotypes of Sepsis-Associated Persistent AKI – Wonsuk Oh
5:15 p.m. FR-OR06 Arterial Stiffness and AKI in the Atherosclerosis Risk in Communities (ARIC) Study – Ester Oh
5:24 p.m. FR-OR07 Noninvasive Identification of Acute Tubular Injury Using Plasma Proteomics – Insa Schmidt
5:33 p.m. FR-OR08 AKI Diagnostic Accuracy and Implications of AKI Baseline Creatinine (ABC) vs. Other Baseline Creatinine Estimating Equations – Erica Bjornstad
5:42 p.m. FR-OR09 Vancomycin-Tacrolimus Combination Increases AKI Risk in Post-Hematopoietic Stem Cell Transplantation (HSCT) Patients – Tuisha Gupta
5:51 p.m. FR-OR10 Heart Failure with Preserved Ejection Fraction (HFrEF) vs. Heart Failure with Reduced Ejection Fraction (HFrEF) After AKI – Bethany Birkelo

Program is subject to change.
Friday, November 3, 4:30 p.m. – 6:00 p.m.

**Development, Organoids, and Genetic Models of Kidney Diseases**

Moderators: Nils Lindström, Kyle McCracken

4:30 p.m.  
**FR-OR11** Role of Biomechanics in the Regulation of Ureteric Bud Branching Morphogenesis  
Satu Kuure

4:39 p.m.  
**FR-OR12** Multi-Omic Profiling of Human Renal Organoids Reveals PAX8 as a Critical Regulator of Human Mesenchymal-to-Epithelial Transition  
Julie Williams

4:48 p.m.  
**FR-OR13** Interpreting Geometric Rules of Early Kidney Formation for Synthetic Morphogenesis  
Alex Hughes

4:57 p.m.  
**FR-OR14** ZEB2 Signaling Is Essential for Ureteral Smooth Muscle Cell Differentiation and Maintenance  
Sudhir Kumar

5:06 p.m.  
**FR-OR15** The Multimodal Role of TBX6 in Kidney and Urinary Tract Development and Disease  
Gregory Whittemore

5:15 p.m.  
**FR-OR16** TGFβ Signaling Regulates Renal Patterning via Cadm1 During Nephrogenesis  
Sara Qubisi

5:24 p.m.  
**FR-OR17** ATP-Citrate Lyase (ACL) Is a Key Modulator of Nephron Progenitor Cell Fate Decisions In Vivo  
Giovane Tortelote

5:33 p.m.  
**FR-OR18** A Single-Cell Atlas of Human Fetal Kidneys Identifies Cell States Associated with Rare and Common Human Disease  
Jonathan Levinsohn

5:42 p.m.  
**FR-OR19** Identification of Genes and Regulatory Elements Affecting Human Kidney Function  
Gabriel Loeb

5:51 p.m.  
**FR-OR20** Genome-Wide Association Study Across Biobanks Identifies New Susceptibility Loci for Urinary Tract Infections  
Katherine Xu

---

**Fluid, Electrolyte, and Acid-Base Disorders: Basic Research**

Moderators: Pablo Ortiz, Shujie Shi

4:30 p.m.  
**FR-OR21** Empagliflozin Blunts Renal Mg2+ Wasting and Restores Distal Tubule Sodium Chloride Cotransporter (NCC) and TRPM6 Expression in Rats with Cisplatin-Induced Hypomagnesemia  
James McCormick

4:39 p.m.  
**FR-OR22** Critical Role of mTORC2 in Maintaining Sodium and Potassium Balance: Implications for Aldosterone-Independent Regulation of Epithelial Sodium Channel (ENaC) in the Distal Nephron  
Bidisha Saha

4:48 p.m.  
**FR-OR23** Role of KLHL3-S433 Phosphorylation in Potassium Homeostasis in Mice – Kenichi Ishizawa

4:57 p.m.  
**FR-OR24** PIEZO1 Channels Are Necessary for BK Channel-Mediated Flow-Induced K+ Secretion (FKS) in the Cortical Collecting Duct (CCD)  
Rolando Carrisoza-Gaytan

5:06 p.m.  
**FR-OR25** The Role of Renal Mechanotransduction in Blood Volume Sensing  
Rose Hill

5:15 p.m.  
**FR-OR26** Kidney Tubular YAP Controls the Expression of Collecting Duct Aquaporins and Water Homeostasis  
Yin Xia

5:24 p.m.  
**FR-OR27** Calcium-Binding Protein 39 (Cab39) Is Required for Na+–Cl− Cotransporter (NCC) Phosphorylation in Mice – Mohammed Ferdaus

5:33 p.m.  
**FR-OR28** Extracellular Calcium-Sensing Receptor (CaSR) and Vasopressin Type 2 Receptor (V2R) Interaction: An Emerging Mechanism to Fine-Tune Water Permeability in Renal Cells  
Mariana Ranieri

5:42 p.m.  
**FR-OR29** Inhibition of Urate Transporters and Insulin-Activated Urate Transport by SGLT2 Inhibitors  
David Mount

5:51 p.m.  
**FR-OR30** ENaC Inhibition with Trimethoprim Occurs Without Changing Urinary H+ Excretion  
Niklas Ayasse
How Sweet It Is: Basics of Diabetic Kidney Disease

Moderators: Michael Eadon, Alla Mitrofanova

4:30 p.m.  
FR-OR31 Decoding the Spatial Transcriptomic Landscape of Diabetic Nephropathy – Qiwen Deng

4:39 p.m.  
FR-OR32 Spatially Localized Mesangial Cell Communication in Diabetic Kidney Disease – Ricardo Melo Ferreira

4:48 p.m.  
FR-OR33 Interferon-γ (IFN-γ) Signaling in Diabetic Kidney Disease (DKD) Associated with ESKD – Viji Nair

4:57 p.m.  
FR-OR34 Metabolomic and Transcriptomic Reveal Signature of Citrate Homeostasis in Diabetic Kidney Disease – Soumya Maity

5:06 p.m.  
FR-OR35 Whole Blood DNA Methylation Signature, Circulating Proteins, and Risk of Progression to ESKD in Type 1 Diabetes (T1D) – Zhuo Chen

5:15 p.m.  
FR-OR36 Single-Cell Resolution Drug Effects on RAAS Blockade in ZSF1 Rat Diabetic Kidney Disease – Michael Balzer

5:24 p.m.  
FR-OR37 Long Noncoding RNA (lncRNA) PVT1 Induces Mitochondrial Damage and Inflammation via TRIM56 in Diabetic Kidney Disease – Zhimei Lv

5:33 p.m.  
FR-OR38 NDUFS4 Regulates Cristae Remodeling in Diabetic Kidney Disease – Koki Mise

5:42 p.m.  
FR-OR39 The Transcription Factor ChREBP Links Mitochondrial Lipidomes to Mitochondrial Morphology and Progression of Diabetic Kidney Disease – Jianyin Long

5:51 p.m.  
FR-OR40 Transcriptomics of SGLT2-Positive Proximal Tubule S1 Segments in Mice: Response to Diabetes, SGLT1/2 Inhibition, or GLP1 Receptor Agonist – Young Chul Kim

Interventions to Reduce CKD Progression

Moderators: Aminu Bello, Sankar Navaneethan

4:30 p.m.  
FR-OR41 Effect of Dietary Acid Reduction on Acid-Base Status of Patients with CKD but with Normal eGFR: A 5-Year Randomized Trial – Nimrit Goraya

4:39 p.m.  
FR-OR42 Supporting Self-Management of Healthy Behaviors (SMART-HABITS) in CKD and Hypertension: A Pilot Trial – Sarah Schrauben

4:48 p.m.  
FR-OR43 Association of Leukotriene Antagonist Use with the Incidence of ESKD – Jessica Kendrick

4:57 p.m.  
FR-OR44 Initiation of ACE Inhibitor and ARBs in Patients with Advanced CKD – Elaine Ku

5:06 p.m.  
FR-OR45 Sotagliflozin and Kidney and Cardiorenal Outcomes in SCORED – David Cherney

5:15 p.m.  
FR-OR46 Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD – Parminder Judge

5:24 p.m.  
FR-OR47 Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial – Hiddo Heerspink

5:33 p.m.  
FR-OR48 Practice Patterns for Patient Pain Control and Outcomes Among CKD Patients: A CKDopps Analysis – Nikhil Nair

5:42 p.m.  
FR-OR49 Implications of Follow-Up Time on the Optimal Weighting of the Acute and Chronic Slopes to Predict Treatment Effects on Clinical End Points – Tom Greene

5:51 p.m.  
FR-OR50 Improvement in Anemia by SGLT2 Inhibitors Were More Prominent Among Those with Inflammation – Miho Murashima
Kidney Pathology: From Classic Clinicopathologic Studies to Computational Pathology .................................................................................................................Room 109
Moderators: Laura Barisoni, Virginie Royal

4:30 p.m. FR-OR51 Membranous-Like Glomerulopathy with Masked Immunoglobulin G (IgG) Kappa Deposits: A Clinicopathologic Analysis of 247 Patients – Tiffany Caza

4:39 p.m. FR-OR52 The Characteristics of Concurrent Anti-Glomerular Basement Membrane Nephritis and Membranous Nephropathy – Lihong Bu

4:48 p.m. FR-OR53 Clinicopathologic Features of Anti-Brush Border Border Antibody Disease: A Series of 66 Patients – Joel Murphy

4:57 p.m. FR-OR54 Clinicopathologic Characteristics, Etiologies, and Outcomes of Secondary Oxalate Nephropathy – Samih Nasr

5:06 p.m. FR-OR55 Computationally Derived Tubular Features Are Prognostic of Clinical Outcomes in Glomerular Kidney Diseases – Fan Fan

5:15 p.m. FR-OR56 Quantitative Characterization of Nonsclerotic Glomeruli Is Prognostic of Clinical Outcomes in Proteinuric Diseases – Akhil Ambekar

5:24 p.m. FR-OR57 A Spatial Atlas of the Human Kidneys of Cell Types and Functional Tissue Units Identified in Highly Multiplexed Immunofluorescence Images – Seth Winfree

5:33 p.m. FR-OR58 Multiplexed Single-Nucleus RNA and ATAC Sequencing in the Renal Biopsy Specimen – Lubin Xu

5:42 p.m. FR-OR59 T-Cell-Receptor (TCR)-Independent Activation of CD8 Effector T Cells by IL-15 and IFNβ Drives Kidney Damage in Lupus Nephritis – Christopher Skopnik

5:51 p.m. FR-OR60 Adoptive Cellular Immunotherapy for the Control of Primary Membranous Nephropathy – Ainhoa Garcia Busquets

Kidney Transplantation: Biomarkers, New and Old..................................................................................................................................Room 115
Moderators: Mohammed Javeed Ansari, Jamil Azzi

4:30 p.m. FR-OR61 Correlation of HLA Matchmaker and PIRCHE Reveals T Cell Epitope Mismatches High Risk for Donor Specific Antibodies (DSA) and Antibody-Mediated Rejection (AMR) – Clarkson Crane

4:39 p.m. FR-OR62 Validation of Diagnostic, Prognostic, and Predictive Performances of a Novel Urinary Exosomal mRNA Clinical Test – Rania El Fekih

4:48 p.m. FR-OR63 Differential cfDNA Methylation in Kidney Allograft Rejection – Benjamin Spector

4:57 p.m. FR-OR64 Urinary Endotrophin Excretion Is Associated with Graft Failure and Mortality in Kidney Transplant Recipients – Firas Alkaff

5:06 p.m. FR-OR65 Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection – Po Yee Mia Leung

5:15 p.m. FR-OR66 Proenkephalin A 119-159 as a Novel Biomarker for Early Detection of Delayed Graft Function After Kidney Transplantation – Christian Nusshag

5:24 p.m. FR-OR67 Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study – Chang Seong Kim

5:33 p.m. FR-OR68 The Molecular Microscope Diagnostics System (MMDx) Does Not Identify Molecular T Cell-Mediated Rejection (TCMR) in Cases with Borderline Changes or Isolated Intimal Arteritis in the Absence of Microvascular Inflammation – Thomas Schachtner

5:42 p.m. FR-OR69 Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients with Indication Biopsy: Results of a Prospective German Single-Center Trial – Louise Benning

5:51 p.m. FR-OR70 Pretransplant HbA1C as a Predictor of Kidney and Pancreas Allograft Survival in Simultaneous Pancreas-Kidney Transplantation: A Retrospective Nationwide Study – Jathurong Kittrakulrat
Managing the Many Facets of Home Dialysis

Moderators: Graham Abra, Nupur Gupta

4:30 p.m.  FR-OR71  The Standardized Discontinuation Ratio: A Novel Measure for Real-Time Monitoring of Home Dialysis Discontinuation – Eric Weinhandl

4:39 p.m.  FR-OR72  Breaking Through Barriers with Home Hemodialysis (HHD) Group Training, Enhancing Access and Improving Patient Experience: A Single-Center Experience – Maria Bermudez

4:48 p.m.  FR-OR73  Hospitalisation Risk in the Integrated Home Dialysis Model: Analysis of the Canadian Organ Replacement Register – Louis-Charles Desbiens

4:57 p.m.  FR-OR74  Physical Activity Perceptions and Practices of People Receiving Peritoneal Dialysis: An International Cross-Sectional Survey – Jennifer MacRae

5:06 p.m.  FR-OR75  Decreasing the Burden: A Single-Centre Experience of Decremental Peritoneal Dialysis (PD) in Toronto, Canada – Shabnam Hamidi

5:15 p.m.  FR-OR76  CKD-Associated Pruritus: Prevalence and Association with Quality of Life for Peritoneal Dialysis Patients, International Results from PDOPPS – Karthik Tennankore

5:24 p.m.  FR-OR77  Outcomes of an Assisted Peritoneal Dialysis Program in the United States – Wael Hussein

5:33 p.m.  FR-OR78  QuickCheck: A Point-of-Care Method for Rapid Cell Counting in Peritoneal Dialysis-Associated Peritonitis – Junaid Qazi

5:42 p.m.  FR-OR79  A Cutting-Edge Multiphoton Microscopy-Based Approach to Test the Structure of the Peritoneal Membrane Reveals the Protective Effects of Glucose-Sparing Solution – Luciano D’Apolito

5:51 p.m.  FR-OR80  Pregnancies in Women with Kidney Failure on Home Dialysis – Silvi Shah

Navigating a Path to Diversity and Equity in Kidney Health

Moderators: Clare Lyas, Ebele Umeukeje

4:30 p.m.  FR-OR81  Representativeness of Randomized Control Trials in Kidney Transplantation – Oshorenu Aiyegbusi

4:39 p.m.  FR-OR82  Primary Care Clinician Perspectives on APOL1 Testing for Kidney Diseases – Dinushika Mohottige

4:48 p.m.  FR-OR83  Association of Unmet Social Needs with Blood Pressure Severity and Target Organ Injury: Interim Analysis of the SUPERHERO Study – Elizabeth Onugha

4:57 p.m.  FR-OR84  Association of Unmet Social Determinants of Health (SDOH) with Quality of Life (QoL) in Patients on Hemodialysis (HD) – Huei Hsun Wen

5:06 p.m.  FR-OR85  Exploring Unconscious Bias in Peer-to-Peer Interactions in Medical Conferences: A Retrospective Analysis – Joseph Wahba

5:15 p.m.  FR-OR86  County-Level Structural Racism Predicts Black-White ESKD Patient Mortality Disparities – Jonathan Daw

5:24 p.m.  FR-OR87  Significant Variation in Kidney Disease Indicators Within Cook County, IL: Findings from Geospatial Analysis of 2022 National Laboratory Data – Jennifer Bragg-Gresham

5:33 p.m.  FR-OR88  Barriers and Opportunities to Increase Home Dialysis Among African American Patients – Unini Odama

5:42 p.m.  FR-OR89  Experiencing Discrimination Reduced the Effectiveness of the TALK Intervention on Kidney Failure Patients – Larissa Myaskovsky

5:51 p.m.  FR-OR90  Regional Variation in the Use of Percutaneous Kidney Biopsy in Japan – Yasuhiro Oda
Friday, November 3, 4:30 p.m. – 6:00 p.m.

**Novel Clinical Impacts on Cardiorenal Disease**

**Room 103**

**Moderators:** Joachim Ix, Nishigandha Pradhan

- **4:30 p.m.**  
  **FR-OR91** One-Month Treatment with Dapagliflozin Triggers Renal Water Conservation and Thus Prevents Osmotic Diuresis in Patients with Chronic Heart Failure  
  - Adriana Marton

- **4:39 p.m.**  
  **FR-OR92** Association of Polygenic Risk Scores for Blood Pressure with Incidence of Hypertension and CKD  
  - Soyeon Kim

- **4:48 p.m.**  
  **FR-OR93** Polygenic Scores for Incident Myocardial Infarction in CKD  
  - Amarnath Marthi

- **4:57 p.m.**  
  **FR-OR94** Kidney Function Trajectories, Risk Factors, and Outcomes in Left Ventricular Assist Device (LVAD) Recipients  
  - Carl Walther

- **5:06 p.m.**  
  **FR-OR95** Associations Between Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Disease in Three Prospective CKD Patient Cohorts  
  - Yang Pan

- **5:15 p.m.**  
  **FR-OR96** Effects of Aprocitentan for Blood Pressure Lowering and Proteinuria in Patients with CKD and Resistant Hypertension  
  - George Bakris

- **5:24 p.m.**  
  **FR-OR97** Increased Coronary Artery Pathology in Type 2 Diabetes Without Cardiovascular Disease but with Albuminuria  
  - Tine Hansen

- **5:33 p.m.**  
  **FR-OR98** Podocyte-Specific Knockout (KO) of the Natriuretic Peptide Clearance Receptor (NPRC) Ameliorates Glomerular Injury in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)  
  - Liming Wang

- **5:39 p.m.**  
  **FR-OR99** Hemizygous Loss of Vegfa in Cap Mesenchyme Is Associated with Thrombotic Microangiopathy and Metabolic Reprogramming of the Thick Ascending Limb (TAL) Epithelium  
  - Dorian Kaminski

- **5:48 p.m.**  
  **FR-OR100** SMPDL3b Modulates Podocyte Innate Immunity via Stimulator of Interferon Genes (STING) Activation in CKD  
  - Antonio Fontanella

- **5:57 p.m.**  
  **FR-OR101** Podocyte-Derived Endothelin-1 and Cross-Talk with Endothelial Cells Through EdnA Is Essential for Glomerular Injury  
  - Ilse Daehn

- **6:06 p.m.**  
  **FR-OR102** Conditional Knockout of YAP Decreases Podocyte Adhesion and Exacerbates FSGS Progression Through α3β1 Integrin  
  - Guangze Shao

- **6:15 p.m.**  
  **FR-OR103** Paracrine Effects of Injured Podocytes on the Transcriptome of Neighboring Cells  
  - Yuting Zeng

- **6:24 p.m.**  
  **FR-OR104** A Novel Small Therapeutic Peptide with Potential for Treating αvβ3-Mediated Glomerular Damage  
  - Yan Xu

- **6:33 p.m.**  
  **FR-OR105** Prevention of Proteinuria by a Novel, Subnanomolar ApoL1 Inhibitor  
  - Brett Antonio

- **6:42 p.m.**  
  **FR-OR106** Dynll1-PI31 Facilitated Proteasome-Mediated Degradation as a New Therapeutic Target for Interferon 2 (INF2)-Related FSGS  
  - Jillian Weidner

- **6:51 p.m.**  
  **FR-OR107** Fasting-Mimicking Diet and Podocyte Protection  
  - Laura Perin

**Podocytopathy: Novel Insights and Emerging Therapeutic Targets**

**Room 108**

**Moderators:** Justin Chun, Haojia Wu

- **4:30 p.m.**  
  **FR-OR98** Podocyte-Specific Knockout (KO) of the Natriuretic Peptide Clearance Receptor (NPRC) Ameliorates Glomerular Injury in a Mouse Model of Focal Segmental Glomerulosclerosis (FSGS)  
  - Liming Wang

- **4:39 p.m.**  
  **FR-OR99** Hemizygous Loss of Vegfa in Cap Mesenchyme Is Associated with Thrombotic Microangiopathy and Metabolic Reprogramming of the Thick Ascending Limb (TAL) Epithelium  
  - Dorian Kaminski

- **4:48 p.m.**  
  **FR-OR100** SMPDL3b Modulates Podocyte Innate Immunity via Stimulator of Interferon Genes (STING) Activation in CKD  
  - Antonio Fontanella

- **4:57 p.m.**  
  **FR-OR101** Podocyte-Derived Endothelin-1 and Cross-Talk with Endothelial Cells Through EdnA Is Essential for Glomerular Injury  
  - Ilse Daehn

- **5:06 p.m.**  
  **FR-OR102** Conditional Knockout of YAP Decreases Podocyte Adhesion and Exacerbates FSGS Progression Through α3β1 Integrin  
  - Guangze Shao

- **5:15 p.m.**  
  **FR-OR103** Paracrine Effects of Injured Podocytes on the Transcriptome of Neighboring Cells  
  - Yuting Zeng

- **5:24 p.m.**  
  **FR-OR104** A Novel Small Therapeutic Peptide with Potential for Treating αvβ3-Mediated Glomerular Damage  
  - Yan Xu

- **5:33 p.m.**  
  **FR-OR105** Prevention of Proteinuria by a Novel, Subnanomolar ApoL1 Inhibitor  
  - Brett Antonio

- **5:42 p.m.**  
  **FR-OR106** Dynll1-PI31 Facilitated Proteasome-Mediated Degradation as a New Therapeutic Target for Interferon 2 (INF2)-Related FSGS  
  - Jillian Weidner

- **5:51 p.m.**  
  **FR-OR107** Fasting-Mimicking Diet and Podocyte Protection  
  - Laura Perin
## Poster Sessions

**Friday, November 3 | Exhibit Hall C**

<table>
<thead>
<tr>
<th>Poster Topics</th>
<th>Board #s</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDDK and Informational Posters – II</td>
<td>INFO01–INFO17</td>
</tr>
<tr>
<td>AI, Digital Health, Data Science – II</td>
<td>001–048</td>
</tr>
<tr>
<td>Educational Research</td>
<td>049–072</td>
</tr>
<tr>
<td>AKI: Epidemiology, Risk Factors, Prevention – I</td>
<td>073–105</td>
</tr>
<tr>
<td>AKI: Outcomes, RRT</td>
<td>106–143</td>
</tr>
<tr>
<td>AKI: Mechanisms – II</td>
<td>144–195</td>
</tr>
<tr>
<td>AKI: Mechanisms – Case Reports</td>
<td>196–234</td>
</tr>
<tr>
<td>Onconephrology: From AKI to CKD and Everything in Between</td>
<td>235–290</td>
</tr>
<tr>
<td>Bone and Mineral Metabolism: Basic</td>
<td>291–321</td>
</tr>
<tr>
<td>Diabetic Kidney Disease: Basic – I</td>
<td>322–378</td>
</tr>
<tr>
<td>Hypertension and CVD: Basic</td>
<td>379–410</td>
</tr>
<tr>
<td>Hemodialysis: Quality of Life, Symptoms, Palliative Care</td>
<td>411–462</td>
</tr>
<tr>
<td>Dialysis: Vascular Access</td>
<td>463–500</td>
</tr>
<tr>
<td>Fluid, Electrolyte, Acid-Base Disorders: Basic</td>
<td>501–543</td>
</tr>
<tr>
<td>Genetic Diseases: Cystic – Basic</td>
<td>544–584</td>
</tr>
<tr>
<td>Genetic Diseases: Tubulopathies</td>
<td>585–632</td>
</tr>
<tr>
<td>Pediatric Nephrology – II</td>
<td>633–675</td>
</tr>
<tr>
<td>Glomerular Diseases: From Inflammation to Fibrosis – II</td>
<td>676–725</td>
</tr>
<tr>
<td>Transplantation: Basic</td>
<td>726–736</td>
</tr>
<tr>
<td>Post-Transplantation and Case Reports</td>
<td>737–790</td>
</tr>
<tr>
<td>Diversity and Equity: Kidney Transplant Research</td>
<td>791–802</td>
</tr>
<tr>
<td>Health Maintenance, Nutrition, Metabolism – II</td>
<td>803–838</td>
</tr>
<tr>
<td>Women’s Health and Kidney Diseases</td>
<td>839–876</td>
</tr>
<tr>
<td>Geriatric Nephrology</td>
<td>877–914</td>
</tr>
<tr>
<td>CKD Epidemiology, Risk Factors, Prevention – II</td>
<td>915–957</td>
</tr>
<tr>
<td>CKD Interventions: Trials and Quality Improvement</td>
<td>958–983</td>
</tr>
<tr>
<td>CKD Mechanisms: From Mendel to Mars</td>
<td>984–1038</td>
</tr>
<tr>
<td>CKD Mechanisms: Progression, Fibrosis, and Beyond</td>
<td>1039–1094</td>
</tr>
<tr>
<td>COVID-19 – II</td>
<td>1095–1139</td>
</tr>
<tr>
<td>NIDDK KUH Summer Undergraduate Research Program</td>
<td>1140–1149</td>
</tr>
</tbody>
</table>

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.

### Wi-Fi Service

Free internet access is available in the convention center throughout the meeting.

---

Program is subject to change.
ASN Career Fair

Meet face-to-face with top employers looking to hire!

November 2–4, 2023
9:30 a.m. – 2:30 p.m.
Located in the Exhibit Hall

ASN invites you to take part in the ASN Career Fair. Connect with employers and find your next nephrology opportunity. It’s FREE to attend!

Be on the lookout for the ASN Featured Employers Guide, including open positions from top employers delivered to your inbox after Kidney Week.

Take charge of your career! Upload or update your resume on the ASN Career Center.

- Get your resume in front of employers hiring nephrology professionals who search the database.
- Search for jobs that are posted right from your smartphone or tablet.
- Be the first to get job alerts when a new position matching your criteria is available.
- Gain resume writing tips and how to prepare for an interview.

Visit careers.asn-online.org to get started!
ASN Publications: Delivering the latest in nephrology science and news

Attend the Best of ASN Journals: JASN, CJASN, and Kidney360 session on Thursday, November 2, at 10:30 a.m. to hear from leading authors on the latest innovative clinical, translational, and basic nephrology research for advancing patient care.

Learn more at asnjournals.org/bestof2023 or scan the QR code using your phone.
Manage Your ASN Kidney Week CME/CE Credits and MOC Points Now

Need ABIM/ABP MOC points?
Don’t forget to submit your reflective statement after claiming CME credits.

ASN’s Continuing Education (CE) program is designed to help nephrology professionals acquire and maintain the knowledge and skillset necessary to improve patient care.

Claim your Kidney Week CME/CE credits in the ASN eLearning Center before December 20, 2023, by following the instructions below:

• Visit asn-online.org/elearning
• Select the Kidney Week 2023 module
• Select the Questionnaire tab; complete the Demographic Questionnaire
• Navigate to the Evaluation tab; complete the General Evaluation and relevant session evaluations
• Go to the Claim Credit tab and follow the onscreen instructions

Accreditation
In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learn more at asn-online.org/elearning or scan the QR code with your mobile device.
# DAY-AT-A-GLANCE
## Saturday, November 4

### 8:00 a.m. – 9:30 a.m.
- Plenary: JASN and CJASN Recognition, Narins Award, Scribner Award, Smith Award and Address, State-of-the-Art Lecture
  - Hall A

### 9:30 a.m. – 2:30 p.m.
- Morning Break (9:30 a.m. – 10:00 a.m.)
- Exhibit Hall C
- Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)
- Exhibit Hall C
- Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)
  - Exhibit Hall C

### 10:00 a.m. – 1:45 p.m.
- Exhibitor Spotlights
  - Exhibit Hall C
- Please see pages 10-11 for the schedule and topics.

### 10:30 a.m. – 12:30 p.m.
- **Basic/Clinical Science Sessions**
  - New Look at Antibody-Mediated Rejection, with the Murphy Endowed Lectureship
  - Room 115
  - Proteinuria and Megalin: Form Meets Function
  - Room 114 (Nutter Theatre)

- **Clinical Practice Sessions**
  - Controversies in CKD: Honoring Jerry Yee
  - Room 204
  - Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?
  - Room 108
  - Emerging Technologies for Kidney Replacement Therapies
  - Room 113
  - Onconeurology: Primer for the Nephrologist
  - Room 201
  - Renal Biopsy: Clinical Correlations 2023
  - Ballroom B
  - Technology-Enabled Kidney Disease Care
  - Room 118

- **Translational Sessions**
  - A Rocky Course: Bones and Stones Through the Life Span
  - Room 119
  - Power of Large Biorepositories in Diabetic Kidney Disease
  - Ballroom A

- **Special Session**
  - ETC Home Stretch? The ESKD Treatment Choices Model, with the Blagg Endowed Lectureship in Kidney Diseases and Public Policy
  - Room 103

- **Oral Abstract Session**
  - High-Impact Clinical Trials: Part 2
  - Hall A

- **Other Event**
  - ASN Innovation Tournament
  - Exhibit Hall C

### 12:45 p.m. – 1:45 p.m.
- Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)
  - Doors open at 12:30 p.m.
  - Cytokines and IgA Nephropathy: Pathogenesis and Novel Therapies
    - Salon A
  - Glucagon-Like Peptide-1 Receptor Agonists Are Becoming Important Players in Diabetic Kidney Disease
    - Salon I
  - Principles of Gout Management in Patients with Kidney Diseases
    - Salon L

### 2:00 p.m. – 4:00 p.m.
- **Basic/Clinical Science Sessions**
  - Genetic Strategies to Guide Therapeutic Development
    - Room 108
  - Innovation in Dialysis: Better Together, Including the Celeste Castillo Lee Endowed Lectureship
    - Room 114 (Nutter Theatre)
  - Maternal and Environmental Factors: Effect on Kidney Formation and Function
    - Room 105

*Program is subject to change.*
2:00 p.m. – 4:00 p.m.

**Basic/Clinical Science Sessions**
- Monitoring Allograft Injury ................................................................. Room 120
- Nephrotic Syndrome: From Structural Classification to Molecular Basis ......................................................... Ballroom A
- Novel Mechanisms of Salt-Sensitive Hypertension .......................................................................................... Room 118
- Novel Roles of Channels and Transporters in Kidney Diseases and CVD .................................................. Room 111
- Podocytopathy in Aging: Advances and Unanswered Questions .................................................................. Room 103
- Updates on Classic and Novel Effects of FGF-23 on Mineral, Bone, and Iron Metabolism .................. Room 119
- What’s Going on in the Interstitium? .............................................................................................................. Room 107

**Clinical Practice Sessions**
- Hiding in Plain Sight: Cases of Drugs as Kidney Toxins ........................................................................ Room 201
- Nephrology Quiz and Questionnaire 2023 ...................................................................................................... Ballroom B
- Therapeutic Controversies in AKI Recovery Care ....................................................................................... Room 204
- We Are Never over the Rainbow: Nephrology Care for the LGBTQ+ Community ................................... Room 109

**Translational Sessions**
- Advances in the Use of Immunofluorescence and Immunohistochemistry in Kidney Biopsy Evaluation ...... Room 113
- Creatinine and Metabolites in Diabetic Kidney Disease .............................................................................. Room 115

4:00 p.m. – 4:30 p.m.

Afternoon Break .......................................................................................... Foyers of Rooms 201/204, 108, 118

4:30 p.m. – 6:00 p.m.

**Clinical Practice Sessions**
- Liquid “Gold,” Urinary Sediment Microscopy: Current Utility of an Old Tool ........................................ Room 204
- Noninfectious Challenges of Home Dialysis Therapies: Improving Patient Retention ..................... Room 113

**Translational Sessions**
- Treatment Development in IgA Nephropathy .......................................................................................... Room 201
- Vascular Aging: Pulsatile Hemodynamics, Arterial Stiffness, and Cardiorenal Target Organ Damage ... Room 114 (Nutter Theatre)

**Oral Abstract Sessions**
- AKI Research: Seeking New Paths to Progress ....................................................................................... Room 118
- Bioengineering, Augmented Intelligence, Digital Health, and Data Science ........................................ Room 118
- COVID-19: A New Understanding and Lessons Learned ........................................................................ Room 107
- Epidemiology of CKD Progression: Who, Why, and When? ................................................................. Room 119
- Fluid, Electrolyte, and Acid-Base Disorders: Clinical Research ............................................................. Room 111
- Glomerular Diseases: From Multiomics to Mechanisms ....................................................................... Room 103
- Hemodialysis Care: Cardiovascular and Patient-Reported Outcomes ................................................. Room 120
- Kidney Transplantation: New Translational Insights .............................................................................. Room 115
- Nutritional and Lifestyle Interventions to Promote Health in CKD ......................................................... Room 109
- Pediatric Nephrology: Clinical and Genetic Studies ............................................................................... Room 105

Download the Kidney Week App
For up-to-date meeting information, search Kidney Week in your app store or scan the QR code here.
Saturday, November 4, 8:00 a.m. – 9:30 a.m

Plenary
8:00 a.m.  JASN and CJASN Recognition
8:10 a.m.  Robert G. Narins Award – Michael Emmett
8:20 a.m.  Belding H. Scribner Award – Philip Li
8:30 a.m.  Homer W. Smith Award and Address “Nephrology Practice and Therapeutics Through a Genomic Lens” – Ali Gharavi
9:00 a.m.  State-of-the-Art Lecture “Antibodies Against Emerging Infectious Diseases: Global Collaborations” – Erica Ollmann Saphire

Saturday, November 4, 10:30 a.m. – 12:30 p.m

New Look at Antibody-Mediated Rejection, Including the Barbara T. Murphy, MB BAO BCh, Endowed Lectureship Room 115
ASN gratefully acknowledges Verici Dx, Renalytix, and the American Society of Transplantation for supporting the Murphy Endowed Lectureship.
Moderators: Enver Akalin, Indira Guleria
10:30 a.m.  Tfh Regulation of Systemic and Graft Alloreactive B Cell Responses After Kidney Transplantation – Peter Sage
11:00 a.m.  Dissecting the Mechanisms of Antibody Generation in Response to Kidney Allografts – Anna Valujskikh
11:30 a.m.  Detection of Memory B Cell Responses Before Alloantibody Generation – Oriol Bestard
12:00 p.m.  Novel Therapeutic Targets to Control Humoral Responses in Desensitization and ABMR: The Barbara T. Murphy, MB BAO BCh, Endowed Lectureship – Flavio Vincenti

Proteinuria and Megalin: Form Meets Function Room 114 (Nutter Theatre)
Moderators: Monica Chang Panesso, Bruce Molitoris
10:30 a.m.  Overview of Filtered Protein Processing in the Proximal Tubule – Andrew Hall
11:00 a.m.  Megalin Structure in Endosomes and at the Surface – Andrew Beenken
11:30 a.m.  Megalin Traffic and Albumin Uptake in Health and Disease – Ora Weisz
12:00 p.m.  Megalin in Rhabdomyolysis-Induced AKI – Michael Hutchens

Controversies in CKD: Honoring Jerry Yee Room 204
ASN thanks the ASN DKD-C Steering Committee for assistance with this session.
Moderators: Michael Choi, Delphine Tuot
10:30 a.m.  HIF-PHIls for Treatment of Anemia: Pro – Steven Fishbane
10:50 a.m.  HIF-PHIls for Treatment of Anemia: Con – Jeffrey Berns
11:10 a.m.  Applying Age-Adapted Cutoffs for CKD: Pro – Andrew Rule
11:30 a.m.  Applying Age-Adapted Cutoffs for CKD: Con – Adeera Levin
11:50 a.m.  Measurement of Urine Albumin vs. Protein: Pro – Josef Coresh
12:10 p.m.  Measurement of Urine Albumin vs. Protein: Con – Holly Kramer

Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels? Room 108
Moderators: Jeffrey Saland, Andrew South
10:30 a.m.  Vascular Effects of Dyslipidemia in Children and Adolescents – Sarah de Ferranti
11:00 a.m.  Dyslipidemia in Pediatric CKD – Smitha Vidi
11:30 a.m.  Adiposity, Dyslipidemia, and Cardiovascular Risk in CKD – Ian Macumber
12:00 p.m.  Controversies in the Management of Dyslipidemia in Children with CKD – Arvind Bagga

52 Program is subject to change.
Emerging Technologies for Kidney Replacement Therapies .............................................. Room 113
Moderators: Crystal Gadegbeku, Sahir Kalim
10:30 a.m. Innovations in Dialysis Access: The Future Is Now – Monnie Wasse
11:00 a.m. The Wearable or Implantable (Bio)Artificial Kidney in 2023 and Beyond – Shuvo Roy
11:30 a.m. Kidney-on-a-Chip: Simulating Kidney Functions – Jonathan Himmelfarb
12:00 p.m. Innovations in Hemodialysis Membranes: Review of the Past and Looking at the Future – Marcos Rothstein

Oncone nephrology: Primer for the Nephrologist .......................................................... Room 201
Moderators: Sheldon Chen, Rimda Wanchoo
10:30 a.m. Approaching AKI and Pseudo-AKI from Cancer Drugs – Abhijat Kitchlu
11:00 a.m. Getting to the Heart of the Matter: Hypertension and Cardiac Disease in Cancer Patients – Prakash Gudsoorkar
11:30 a.m. Managing Kidney Transplant Patients with Cancer – Naoka Murakami
12:00 p.m. Providing Compassionate Care to Patients with Cancer and Kidney Diseases – Jennifer Scherer

Renal Biopsy: Clinical Correlations 2023 .................................................................. Ballroom B
ASN thanks the Renal Pathology Society for assistance with this session.
Moderators: Nicole Andeen, Jean Hou
Clinical Discussant: William Whittier
10:30 a.m. Renal Pathology Case Study 1 – Anatoly Urisman
11:00 a.m. Renal Pathology Case Study 2 – Matthew Palmer
11:30 a.m. Renal Pathology Case Study 3 – Laura Biederman
12:00 p.m. Renal Pathology Case Study 4 – Carmen Avila-Casado

Technology-Enabled Kidney Disease Care ..................................................................... Room 118
Moderators: Stanley Crittenden, Janice Lea
10:30 a.m. Integrated Digital Health System Tools to Support Decision Making and Treatment Preparation in CKD – Jamie Green
11:00 a.m. Telenephrology Provider Perspectives and Clinical Outcomes – Gaurav Jain
11:30 a.m. Use of Patient-Facing Mobile Technology and Remote Patient Monitoring in Kidney Diseases – Priya Deshpande
12:00 p.m. Wearable Sensors in the Treatment of CKD and ESKD – Jeroen Kooman

ETC Home Stretch? The ESKD Treatment Choices Model, Including the Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy .................................. Room 103
ASN gratefully acknowledges the Northwest Kidney Centers and its contributors for support of the Blagg Lectureship. ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.
Moderators: Keith Bellovich, Edward Gould
10:30 a.m. ETC Two Years In: How Did We Get Here and Where Are We Going? – Daniel Weiner
11:00 a.m. Lessons from Around the World: Building an Environment for Successful Home Dialysis – Martin Wilkie
11:30 a.m. Metrics and the Challenge of Improving Access to Kidney Transplantation: The Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy – Sumit Mohan
12:00 p.m. Navigating the New Paradigm of Kidney Care – Suzanne Watnick
A Rocky Course: Bones and Stones Through the Life Span .................................................... Room 119
Moderators: Stuart Sprague, Katherine Wesseling-Perry
10:30 a.m.  Bone Health in Children with Nephrolithiasis: Is the Die Cast Early? – Michelle Denburg
11:00 a.m.  Bone Health Across the Stone-Forming Life Span – Ita Heilberg
11:30 a.m.  Role of Diet and Medical Therapy in the Treatment and Prevention of Bone Disease in Stone Formers – Calyani Ganesan
12:00 p.m.  Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1 – David Sas

Power of Large Biorepositories in Diabetic Kidney Disease .................................................... Ballroom A
Moderators: Hiddo Heerspink, Peter Rossing
10:30 a.m.  Pima Indian Kidney Study – Robert Nelson
11:00 a.m.  TRIDENT Trial: Transformative Research In Diabetic Nephropathy – Katalin Susztak
11:30 a.m.  Power of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repositories – Afshin Parsa
12:00 p.m.  Nonfederal Funding Opportunities: Leveraging Large Biorepositories – Sanjoy Dutta

High-Impact Clinical Trials: Part 2.................................................................................................. Hall A
Please check the Kidney Week app or the ASN website for session details.

ASN Innovation Tournament ..................................................................................................... Exhibit Hall C
Note: Continuing education credits are not being offered for this activity.

Saturday, November 4, 12:45 p.m. – 1:45 p.m.

Educational Symposia (Philadelphia Marriott Downtown, Level 5, Grand Ballroom)
Doors open at 12:30 p.m. Lunch is provided.
Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Cytokines and IgA Nephropathy: Pathogenesis and Novel Therapies .................................Salon A
Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.
12:45 p.m.  Introduction – Ali Gharavi (Moderator)
12:55 p.m.  Roles of APRIL and BAFF in the Pathogenesis of IgA Nephropathy – Hitoshi Suzuki
1:15 p.m.  Therapies Targeting BAFF and APRIL in IgA Nephropathy – Heather Reich
1:35 p.m.  Questions and Answers

Glucagon-Like Peptide-1 Receptor Agonists Are Becoming Important Players in Diabetic Kidney Disease ...............................................................Salon I
Support is provided by an educational grant from Novo Nordisk.
12:45 p.m.  Introduction – Uta Erdbruegger (Moderator)
12:55 p.m.  GLP1 RAs and Kidney Outcomes in Diabetes – Katherine Tuttle
1:15 p.m.  GLP1 RAs as a Part of the Diabetic Kidney Disease Therapeutic Landscape – Sylvia Rosas
1:35 p.m.  Questions and Answers

Program is subject to change.
Saturday, November 4, 12:45 p.m. – 1:45 p.m.

**Principles of Gout Management in Patients with Kidney Diseases**

*Support is provided by an educational grant from Horizon Therapeutics USA, Inc.*

- **12:45 p.m.** Introduction – Paul Palevsky (Moderator)
- **12:55 p.m.** Pathophysiology of Hyperuricemia and Gout – Richard Johnson
- **1:15 p.m.** Management of Complex Patients with Gout: Special Considerations in CKD and ESKD – Angelo Gaffo
- **1:35 p.m.** Questions and Answers

Saturday, November 4, 2:00 p.m. – 4:00 p.m.

**Genetic Strategies to Guide Therapeutic Development**

*Room 108*

Moderators: Rasheed Gbadegesin, Matthew Wilson

- **2:00 p.m.** Potential of RNA-Based Therapy for Kidney Diseases – Eun ji Chung
- **2:30 p.m.** Antisense Oligonucleotide Therapy in APOL1 Nephropathy – Barry Freedman
- **3:00 p.m.** Gene Therapy in IgA Nephropathy – Jonathan Barratt
- **3:30 p.m.** Gene Read Through Therapies in Alport Syndrome – Ali Hariri

**Innovation in Dialysis: Better Together,**

*Including the Celeste Castillo Lee Endowed Lectureship*  
*Room 114 (Nutter Theatre)*

ASN gratefully acknowledges Travere Therapeutics and several of Celeste’s family members, friends, and colleagues for support of the Celeste Castillo Lee Endowed Lectureship.

Moderators: Kerri Cavanaugh, Lisa Koester Wiedemann

- **2:00 p.m.** Co-Productive Studies of Decision Making in Kidney Replacement Therapy – Jane Noyes
- **2:30 p.m.** Innovation in Dialysis: How Should We Measure Success? – Laura Dember
- **3:00 p.m.** PROs and PROMs Are What Matter Most to Patients: The Celeste Castillo Lee Endowed Lectureship – Amanda Grandinetti
- **3:30 p.m.** Patient-Centered Approaches to Symptom Control – Kamyar Kalantar-Zadeh

**Maternal and Environmental Factors: Effect on Kidney Formation and Function**

*Room 105*

Moderators: Vikas Dharnidharka, Sunder Sims-Lucas

- **2:00 p.m.** Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm – Jennifer Charlton
- **2:30 p.m.** Maternal Insults and Susceptibility Later in Life – Kimberly Reidy
- **3:00 p.m.** Environmental Insults and Kidney Formation and Function – Alison Sanders
- **3:30 p.m.** Kidney Derangements Seen in Childhood due to Prenatal Insults – Andrew South

**Monitoring Allograft Injury**

*Room 120*

Moderators: Akansha Agrawal, Valeria Mas

- **2:00 p.m.** Blood Gene Transcripts – Maarten Naesens
- **2:30 p.m.** Spatial Transcriptomics of Graft Biopsies: Can Rejection and No Rejection Coexist? – Paolo Cravedi
- **3:00 p.m.** Urinary Biomarkers – Rania El Fekih
- **3:30 p.m.** Intragraft Gene Transcript Detection – Enver Akalin
Saturday, November 4, 2:00 p.m. – 4:00 p.m.

Nephrotic Syndrome: From Structural Classification to Molecular Basis.......................... Ballroom A
ASN thanks the Renal Pathology Society for assistance with this session.
Session support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Shreeram Akilesh, Rachel Lennon
2:00 p.m.  Current Classification of FSGS and Minimal Change Disease – Thomas Benzing
2:30 p.m.  Enhancing Classification of FSGS and Minimal Change Disease with Digital and Computational Pathology – Laura Barisoni
3:00 p.m.  T and B Cell Dysregulation in Idiopathic Nephrotic Syndrome – Marina Vivarelli
3:30 p.m.  Autoimmunity and Idiopathic Nephrotic Syndrome – Astrid Weins

Novel Mechanisms of Salt-Sensitive Hypertension ....................................................... Room 118
Moderators: Cary Boyd-Shiwarski, Orson Moe
2:00 p.m.  ENaC-Dependent Inflammasomes in Hypertension – Annet Kirabo
2:30 p.m.  Mitochondrial Dysfunction in the Pathogenesis of Salt-Sensitive Hypertension – Allen Cowley
3:00 p.m.  Lysine Metabolism and Kidney Protection in Salt-Sensitive Hypertension – Alexander Staruschenko
3:30 p.m.  Epigenetic Mechanisms of Salt-Sensitive Hypertension – Toshiro Fujita

Novel Roles of Channels and Transporters in Kidney Diseases and CVD ......................... Room 111
Moderators: Lei Wang, Owen Woodward
2:00 p.m.  Novel Role of Histamine Receptors in the Regulation of Renal Epithelial Sodium Channel (ENaC) – Daria Ilatovskaya
2:30 p.m.  Targeting the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Calcium: A New Therapeutic Approach to PKD – Liudmila Cebotaru
3:00 p.m.  Mechanosensitive Piezo1 Channels Mediate Kidney Fibrosis – Weidong Wang
3:30 p.m.  Inhibition of Urea Transporter Ameliorates Uremic Cardiomyopathy in CKD – Jeff Sands

Podocytopathy in Aging: Advances and Unanswered Questions................................. Room 103
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Jeffrey Miner, Clintoria Williams
2:00 p.m.  Podocyte Mitochondria as Therapeutic Targets in Aging – Mariya Sweetwyne
2:30 p.m.  Exploring the GSK3b as a Therapeutic Target in Podocyte Senescence – Rujun Gong
3:00 p.m.  HDACs and Podocyte Senescence: Novel Therapeutic Targets? – Shuta Ishibe
3:30 p.m.  Considering the Role of REST in Podocyte Aging – Guillaume Canaud

Updates on Classic and Novel Effects of FGF-23 on Mineral, Bone, and Iron Metabolism................................................................. Room 119
Moderators: Mark Hanudel, Tally Naveh-Many
2:00 p.m.  Overview of Classical Functions of FGF-23 in CKD, Including Contribution to Pathogenesis of CKD-MBD – Kenneth White
2:30 p.m.  Review of Metabolic Mechanisms for FGF-23 Elevation in CKD – Petia Simic
3:00 p.m.  Effects of FGF-23 on Bone – Aline Martin
3:30 p.m.  Systemic Effects of FGF-23 Peptides on Iron Metabolism – Guillaume Courbon
### Saturday, November 4, 2:00 p.m. – 4:00 p.m.

#### What’s Going on in the Interstitium? ..................................................................................... Room 107
**Moderators:** Satu Kuure, Norman Rosenblum
- **2:00 p.m.** *Stroma Cell Types and Mechanotransduction in the Kidneys* – Thomas Carroll
- **2:30 p.m.** *Neurovascular Networks in Kidney Development* – Lori O’Brien
- **3:00 p.m.** *Dynamics and Heterogeneity of Kidney Lymphatics in Organogenesis* – David Long
- **3:30 p.m.** *3D Kidney Interstitial Matrix* – Sarah Calve

#### Hiding in Plain Sight: Cases of Drugs as Kidney Toxins ...................................................... Room 201
**Moderators:** Magdalene Assimon, Stuart Goldstein
- **2:00 p.m.** *Check Yourself: Immune Checkpoint Inhibitor Nephrotoxicity* – Sandra Herrmann
- **2:30 p.m.** *Piperacillin/Tazobactam and Vancomycin Nephrotoxicity: Fact or Fiction* – Alexander Flannery
- **3:00 p.m.** *Detecting New Nephrotoxins in an Era of Big Data* – Sandra Kane-Gill
- **3:30 p.m.** *Cases of Nephrotoxin Stewardship* – Christine Stoops

#### Nephrology Quiz and Questionnaire 2023 ........................................................................... Ballroom B
**Moderators:** Beatrice Concepcion, Melanie Hoenig
- **2:00 p.m.** *Electrolyte and Acid-Base Disturbances* – Roger Rodby
- **2:30 p.m.** *Glomerular Diseases* – Dia Waguespack
- **3:00 p.m.** *Transplantation* – Gaurav Gupta
- **3:30 p.m.** *Kidney Replacement Therapy* – Bessie Young

#### Therapeutic Controversies in AKI Recovery Care ................................................................. Room 204
*ASN thanks the ASN AKINow Recovery/Post-AKI Workgroup for assistance with this session.*
**Moderators:** Erin Barreto, Samuel Silver
- **2:00 p.m.** *Press Your Luck: Targets and Tactics to Manage BP in AKI Survivors* – Ian McCoy
- **2:30 p.m.** *The Who, When, and How of RAS/SGLT2 Inhibitors in AKI Survivors* – Emily See
- **3:00 p.m.** *Dialysis Distinctions: AKI vs. ESKD* – Ayse Akcan Arikan
- **3:30 p.m.** *Under the Weather: Sick Day Protocols in AKI Survivors* – Jia Hwei Ng

#### We Are Never over the Rainbow: Nephrology Care for the LGBTQ+ Community .......... Room 109
*ASN thanks the ASN Diversity, Equity, and Inclusion Committee for assistance with this session.*
**Moderators:** Han Eckenrode, Suzanne Martin
- **2:00 p.m.** *Health Care Disparities in the LGBTQ+ Community* – Yuvaram Reddy
- **2:30 p.m.** *Intersectionality: How Race and Class Interact with LGBTQ+ Identity to Impact Health Outcomes* – Dinushika Mohottige
- **3:00 p.m.** *AKI and CKD Care in Transgender Patients* – David Collister
- **3:30 p.m.** *Transplant Care in Transgender Patients* – Samira Farouk
Saturday, November 4, 2:00 p.m. – 4:00 p.m.

**Advances in the Use of Immunofluorescence and Immunohistochemistry in Kidney Biopsy Evaluation** ................................................................. **Room 113**
Moderators: Mariam Alexander, Zoltan Laszik
2:00 p.m.  **Evaluating for Monotypic Deposits: Beyond the Usual Immunofluorescence Panel** – Dominick Santoriello
2:30 p.m.  **Using Immunohistochemistry to Assess Complement Activation in the Kidney Biopsy** – Nicholas Medjeral-Thomas
3:00 p.m.  **Using Artificial Intelligence in the Analysis of Kidney Immunofluorescence** – Riccardo Magistroni
3:30 p.m.  **Using Highly Multiplexed Immunofluorescence to Further Understanding of Kidney Diseases** – Angela Sabo

**Creatinine and Metabolites in Diabetic Kidney Disease** ................................................................. **Room 115**
Moderators: Anna Mathew, Eugene Rhee
2:00 p.m.  **GFR in Current Clinical Guidelines** – Pierre Delanaye
2:30 p.m.  **GFR in Clinical Research: Revisited** – Alessandro Doria
3:00 p.m.  **Metabolomics in Diabetic Kidney Disease** – Morgan Grams
3:30 p.m.  **Lipidomics in Diabetic Kidney Disease** – Subramaniam Pennathur

Saturday, November 4, 4:30 p.m. – 6:00 p.m.

**Liquid “Gold,” Urinary Sediment Microscopy: Current Utility of an Old Tool** .................. **Room 204**
Moderators: Isabelle Ayoub, Corey Cavanaugh
4:30 p.m.  **Evidence for Urine Microscopy in Acute Tubular Injury Diagnosis and Prognosis** – Juan Carlos Velez
5:00 p.m.  **Urine Microscopy in “AKI-itis”: GN and AIN** – Florian Buchkremer
5:30 p.m.  **Value of Urine Microscopy in Clinical Practice: Illustration by Cases** – Jay Seltzer

**Noninfectious Challenges of Home Dialysis Therapies: Improving Patient Retention ... Room 113**
ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.
Moderators: Fredric Finkelstein, Eric Wallace
4:30 p.m.  **Knowledge Is Key: Increasing the Use of Home Dialysis Through Patient Education** – Bourne Auguste
4:50 p.m.  **Home Hemodialysis Vascular Access Complications** – Brent Miller
5:10 p.m.  **Prescribing Peritoneal Dialysis for Anuric Patients** – Annie-Claire Nadeau-Fredette
5:30 p.m.  **Peritoneal Dialysis Catheter Challenges: Malfunctions, Pain, and Leaks** – Osama El Shamy

**Treatment Development in IgA Nephropathy** ................................................................. **Room 201**
ASN thanks the Kidney Health Initiative for assistance with this session.
Session support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Mark Lim, Patrick Nachman
4:30 p.m.  **Perspective and Journey of a Parent Diagnosed with IgA Nephropathy** – Judy Akin
4:50 p.m.  **Trial Design and Endpoints in IgA Nephropathy** – Heather Reich
5:10 p.m.  **Regulatory Pathways for Drug Development, Including the Accelerated Approval Pathway** – Aliza Thompson
5:30 p.m.  **Emerging Therapies in IgA Nephropathy** – Dana Rizk
Saturday, November 4, 4:30 p.m. – 6:00 p.m.

Vascular Aging: Pulsatile Hemodynamics, Arterial Stiffness, and Cardiorenal Target Organ Damage .......................................................... Room 114 (Nutter Theatre)
Moderators: Wendy McCallum, Mahboob Rahman
4:30 p.m. Pathophysiology of Abnormal Pulsatile Hemodynamics and Arterial Stiffness – Julio Chirinos
4:50 p.m. What Is Arterial Stiffness and How Is It Measured? – Elaine Urbina
5:10 p.m. Arterial Stiffness and Pulsatile Hemodynamics in CKD – Raymond Townsend
5:30 p.m. Pathogenic Role of Arterial Stiffness in Cerebrovascular Disease and Dementia – Timothy Hughes
## Oral Abstract Sessions

### AKI Research: Seeking New Paths to Progress

**Room 118**

Moderators: Rhea Bhargava, Kianoush Kashani

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.</td>
<td><strong>SA-OR01</strong> IMPROVE AKI: Sustainability of Team-Based Coaching Interventions to Improve AKI in a Cluster-Randomized Trial</td>
<td>Michael Matheny</td>
</tr>
<tr>
<td>4:39 p.m.</td>
<td><strong>SA-OR02</strong> Effects of Avasopasem Manganese on Cisplatin-Induced AKI and CKD</td>
<td>Benjamin Griffin</td>
</tr>
<tr>
<td>4:48 p.m.</td>
<td><strong>SA-OR03</strong> Effect of Terlipressin Treatment on the Incidence of Renal Replacement Therapy in Patients with Hepatorenal Syndrome and Fluid Overload: A Post Hoc Analysis of the Phase 3 CONFIRM Study</td>
<td>Hani Wadei</td>
</tr>
<tr>
<td>4:57 p.m.</td>
<td><strong>SA-OR04</strong> Niacinamide and Renal Recovery After AKI: A Randomized, Controlled Trial</td>
<td>Harbir Kohli</td>
</tr>
<tr>
<td>5:06 p.m.</td>
<td><strong>SA-OR05</strong> Impact of Using Blood Warmer During Continuous Kidney Replacement Therapy on Adverse Kidney Events and Mortality</td>
<td>Aisha Abbasi</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td><strong>SA-OR06</strong> Machine Learning-Guided Personalized Diuretic Strategy in Patients with Sepsis-Associated AKI</td>
<td>Wonsuk Oh</td>
</tr>
<tr>
<td>5:24 p.m.</td>
<td><strong>SA-OR07</strong> Association of Post-Hospitalization Vascular Biomarker Clusters with Future Heart Failure</td>
<td>Audrey Shi</td>
</tr>
<tr>
<td>5:33 p.m.</td>
<td><strong>SA-OR08</strong> The Association of Female Sex Hormones and AKI</td>
<td>Ladan Golestaneh</td>
</tr>
<tr>
<td>5:42 p.m.</td>
<td><strong>SA-OR09</strong> Dialysis Weaning Is Uncommon in the Treatment of Outpatient AKI</td>
<td>Ian McCoy</td>
</tr>
<tr>
<td>5:51 p.m.</td>
<td><strong>SA-OR10</strong> Prediction of Postdischarge Kidney Disease Progression Among Patients with Hospitalized AKI: The ASSESS-AKI Study</td>
<td>Steven Menez</td>
</tr>
</tbody>
</table>

### Bioengineering, Augmented Intelligence, Digital Health, and Data Science

**Room 108**

Moderators: Weining Lu, Pinaki Sarder

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.</td>
<td><strong>SA-OR11</strong> Development of Physiologically Relevant In Vitro Model of Human Kidney Collecting Duct System Toward a Functional Kidney Replacement</td>
<td>Shayan Gholizadeh</td>
</tr>
<tr>
<td>4:39 p.m.</td>
<td><strong>SA-OR12</strong> Induced Pluripotent Stem Cell (iPsc)-Derived and Primary Podocyte-Like Cells Are Capable of Macromolecular Sieving After Culture in Scalable Scaffolds</td>
<td>Thomas Gallegos</td>
</tr>
<tr>
<td>4:48 p.m.</td>
<td><strong>SA-OR13</strong> A Novel Vascularized Human Kidney Organoid to Study Podocyte and Endothelial Health and Disease</td>
<td>Joseph Maggiore</td>
</tr>
<tr>
<td>4:57 p.m.</td>
<td><strong>SA-OR14</strong> A Mouse Glomerular Nanoscale Spatial Atlas</td>
<td>Adilijiang Ali</td>
</tr>
<tr>
<td>5:06 p.m.</td>
<td><strong>SA-OR15</strong> A Novel Glomerular Endothelium-Targeting Adeno-Associated Virus (AAV) Delivers Bacterial Proteinase to Treat Glomerulonephritis</td>
<td>Shuya Liu</td>
</tr>
<tr>
<td>5:15 p.m.</td>
<td><strong>SA-OR16</strong> Comprehensive Single-Cell Transcriptomic, Epigenomic, and Metabolomic Profiling Reveals Anatomical and Metabolic Heterogeneity in Human Kidneys</td>
<td>Haikuo Li</td>
</tr>
<tr>
<td>5:24 p.m.</td>
<td><strong>SA-OR17</strong> Improving Patient Activation via a Novel Digital Health Intervention: My Kidneys and Me, a Multicenter Randomized Controlled Trial</td>
<td>Courtney Lightfoot</td>
</tr>
<tr>
<td>5:33 p.m.</td>
<td><strong>SA-OR18</strong> The Effect of a Novel Digital Physical Activity Intervention on Health-Related Quality of Life in People with CKD: A Multicenter Randomized Controlled Trial (Kidney BEAM)</td>
<td>Sharlene Greenwood</td>
</tr>
<tr>
<td>5:42 p.m.</td>
<td><strong>SA-OR19</strong> Hemodialysis Patient App Promotes Patient Engagement and May Improve Patient Outcomes Such as Hospitalisation and Phosphate Control</td>
<td>Milind Nikam</td>
</tr>
<tr>
<td>5:51 p.m.</td>
<td><strong>SA-OR20</strong> Integrated Proteomic and Metabolomic Modules Associated with Risk of Kidney Function Decline</td>
<td>Pascal Schlosser</td>
</tr>
</tbody>
</table>
Saturday, November 4, 4:30 p.m. – 6:00 p.m.

COVID-19: A New Understanding and Lessons Learned ......................................................... Room 107
Moderators: Michelle Hladunewich, Jeffrey Silberzweig

4:30 p.m.  
SA-OR21  A Soluble ACE2 Protein Improves Survival and lowers Viral Titers in a Lethal Mouse Model of SARS-CoV-2 Infection with the Delta Variant – Cosimo Cianfarini

4:39 p.m.  
SA-OR22  University of California Health Systems Kidney COVID Study Inpatient Cohort – Hiba Hamdan

4:48 p.m.  
SA-OR23  Machine Learning-Based Multi-Omics Analyses Predict Disease Severity and Identify Molecular Mechanisms of COVID-Associated Kidney Injury – Nanditha Anandakrishnan

4:57 p.m.  
SA-OR24  Longitudinal Kidney Outcomes of COVID-19-Associated AKI – Abinet Aklilu

5:06 p.m.  
SA-OR25  Monovalent and Bivalent mRNA Vaccine Effectiveness Against Severe COVID-19 Associated with Omicron Variant in Maintenance Dialysis Patients – Nien Chen Li

5:15 p.m.  
SA-OR26  Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider – Eric Weinhandl

5:24 p.m.  
SA-OR27  Kidney Transplant Graft Loss During 2020 – Kirsten Johansen

5:33 p.m.  
Invited Lecture  RAS Inhibition in COVID: The Trial Evidence – Meg Jardine

Epidemiology of CKD Progression: Who, Why, and When? ......................................................... Room 119
Moderators: Teresa Chen, Edgar Lerma

4:30 p.m.  
SA-OR28  Abrupt Estimated Glomerular Filtration Rate Decline After Initiating Sodium-Glucose Cotransporter-2 Inhibitors Predicts Clinical Outcomes: A Systematic Review – Yu-Shuo Tang

4:39 p.m.  
SA-OR29  Global Burden of CKD and Attributable Risk Factors in 38 Organization for Economic Cooperation and Development (OECD) Countries: Results from GBD 2019 – Hardik Desai

4:48 p.m.  
SA-OR30  The Risk of CKD in Lithium-Treated Individuals – Gisli Gislason

4:57 p.m.  

5:06 p.m.  
SA-OR32  Mortality and Transplant After Delivering on Hemodialysis: A Matched Cohort Study – Andrea Oliverio

5:15 p.m.  
SA-OR33  Performance of Creatinine-Based GFR Estimating Equations in Young Adults – Lesley Inker

5:24 p.m.  
SA-OR34  Discrepancy Between eGFR Cystatin C and eGFR Creatinine in Recently Hospitalized Adults – Yumeng Wen

5:33 p.m.  
SA-OR35  Comprehensive Evaluation of CKD Heat Map – Morgan Grams

5:42 p.m.  
SA-OR36  Hospital Health Care Costs Following Incident CKD in Japan, Sweden, and the United States – Navdeep Tangri

5:51 p.m.  
SA-OR37  External Validation of the Klinrisk Model in US Commercial, Medicare Advantage, and Medicaid Populations – Navdeep Tangri
**Saturday, November 4, 4:30 p.m. – 6:00 p.m.**

**Fluid, Electrolyte, and Acid-Base Disorders: Clinical Research**

**Moderators:** Evan Ray, Joshua Rein

- **4:30 p.m.** SA-OR38 The Effect of Thiazide Diuretics on Urinary Prostaglandin E2 Excretion and Serum Sodium in the General Population – Crissy Rudolphi

- **4:39 p.m.** SA-OR39 The Plasma Metabolome and Risk of Incident Kidney Stones – Pietro Manuel Ferraro

- **4:48 p.m.** SA-OR40 Dietary Potassium and Potassium Supplementation Differentially Affect Plasma Potassium in Patients with CKD – Martin Gritter

- **4:57 p.m.** SA-OR41 HARMONIZE ASIA: A Phase 3 Study to Investigate the Safety and Efficacy of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China – June Zhao

- **5:06 p.m.** SA-OR42 Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients with Chronic Syndrome of Inappropriate Antidiuresis (SIAD): A Monocentric Open-Label Proof-of-Concept Study – Sophie Monnerat

**Glomerular Diseases: From Multimomics to Mechanisms**

**Moderators:** R. Tyler Miller, Ambra Pozzi

- **4:30 p.m.** SA-OR88 IFNγ-Induced APOL1 Expression and Pyroptotic Angiopathy in Human Kidney Organoids Mirrors a Nephrotic Gene Signature in Patient Biopsies – Benjamin Juliaar

- **4:39 p.m.** SA-OR89 Plasma Proteome Profiling for Remission Diagnosis in ANCA Vasculitis – Ralph Kettritz

- **4:48 p.m.** SA-OR90 Development of Novel Selective DDR1 Inhibitors with the Potential to Treat CKD – Nicolas Guisot

- **4:57 p.m.** SA-OR91 Spatial Metabolomics Identifies Novel Glomerular Metabolite Signatures of Normal and Diabetic Kidneys – Leila Hejazi

- **5:06 p.m.** SA-OR92 Single-Nucleus Transcriptome Profiling of the Kidney Glomerulus Identifies Cell-Specific Responses in an Autoimmune Model of Membranous Nephropathy – Ming Huang

- **5:15 p.m.** SA-OR93 Lymphangiogenesis Regulates the Differentiation and Function of Th1 Cells in Experimental Anti-Glomerular Basement Membrane (GBM) Crescentic Glomerulonephritis (cGN) – Danni Hu

- **5:24 p.m.** SA-OR94 Bub1 Is a Potential Mediator of TGFβ-Induced Renal Fibrosis – Yasuhiro Onishi

- **5:33 p.m.** SA-OR95 Protective Role of RBPjk in HIV-Related CKD – Madhulika Sharma

- **5:42 p.m.** SA-OR96 Changes in Gene Expression in Fatty Acid Metabolism and De Novo Lipogenesis Are Conserved in Human CKD and Animal Models – Lauren Elizabeth Lee

- **5:51 p.m.** SA-OR97 Humanized IGHA1 Mouse Induced by Lactobacillus casei Cell Wall Extract: A Novel Galactose-Deficient Immunoglobulin A1 (IgA1) Elevated Mouse Model of IgA Nephropathy – Run Li
Hemodialysis Care: Cardiovascular and Patient-Reported Outcomes

Moderators: Rita McGill, Harini Sarathy

4:30 p.m.  SA-OR48 Role of Midodrine in Prevention of Intradialytic Hypotension: A Randomized Cross-Over Controlled Trial – Pajaree Krisanapan

4:39 p.m.  SA-OR49 Association of Calcium Channel Blocker Use with Intradialytic Hypotension – Armida lefranc Torres

4:48 p.m.  SA-OR50 Association Between Ultrafiltration Rates and All-Cause Death in Patients Undergoing Extended-Hours Hemodialysis Using Time-Fixed and Time-Dependent Models: The LIBERTY Cohort – Takahiro Imaizumi

4:57 p.m.  SA-OR51 Impact of ESRD on Stroke Risk in Atrial Fibrillation Patients – Abdallah El Bizri

5:06 p.m.  SA-OR52 Use and Association of Rate Control and Anti-Arrhythmic Medications with Risk of Subsequent Stroke and Mortality Among Hemodialysis Patients with Atrial Fibrillation – Benjamin Lidgard

5:15 p.m.  SA-OR53 Hemoglobin Stability in the ASCEND-TD Trial – Anjali Acharya

5:24 p.m.  SA-OR54 Depletion of Plasma Aromatic Amino Acids During Hemodialysis Is Associated with Fatigue – Subrata Debnath

5:33 p.m.  SA-OR55 Association Between Circulating Extracellular Matrix (ECM)-Associated Molecules and Cardiovascular Outcomes in Hemodialysis Patients – Jihyun Baek

5:42 p.m.  SA-OR56 Plasma Aβ42/Aβ40 Ratio as a Biomarker for Cognitive Impairment in Patients Undergoing Hemodialysis: A Multicenter Study – Xujiao Chen

5:51 p.m.  SA-OR57 Using Internal Pilot Data to Create a Dynamic Recruitment Strategy: Experience from the NightLife Trial – Katherine Hull

Kidney Transplantation: New Translational Insights

Moderators: Venkatesh Kumar Ariyamuthu, Ibrahim Tawhari

4:30 p.m.  SA-OR58 Posoleucel Associated with Reduction of BK Viremia and Persistence of BK-Reactive T Cells in a Phase 2 Trial – Anil Chandraker

4:39 p.m.  SA-OR59 A Phase 1/2a Trial of Autologous Regulatory T Cell Therapy Together with Donor Bone Marrow Infusion in Kidney Transplantation – Rainer Oberbauer

4:48 p.m.  SA-OR60 Reduction of Renal Graft Fibrosis with Valganciclovir Prophylaxis for Cytomegalovirus Prevention Compared to Preemptive Therapy: Long-Term Outcomes of Randomized Controlled Trial (OVERT Study) – Tomas Reischig

4:57 p.m.  SA-OR61 Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database – Nageen Anwar

5:06 p.m.  SA-OR62 Deceased Donor Kidney Function Is Determined by Branch Chained Amino Acid Metabolism During Ex Vivo Normothermic Perfusion – Armin Ahmadi

5:15 p.m.  SA-OR63 The Association Between V-Set Ig Domain-Containing 4 (Vsig4) Expression and Chronicity in Transplant Kidneys – Sang Youb Han

5:24 p.m.  SA-OR64 Overlapping Pathologic Findings in the Kidney Allograft Biopsy: Pitfalls for the Molecular Microscope Diagnostics System (MMDx) – Thomas Schachtner

5:33 p.m.  SA-OR65 The Impact of Subclinical T Cell-Mediated Rejection on Subsequent Rejections and Allograft Survival in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis – Takayuki Yamada

5:42 p.m.  SA-OR66 Cell Subtypes and Cell-Specific Pathways Associated with Acute-to-Chronic Injury Transition in Posttransplant AKI – Enver Akalin

5:51 p.m.  SA-OR67 Suitability to Donate and Attitude Toward Living Kidney Donation in Older Adults: Results from the BIS Study – Cédric Villain
Nutritional and Lifestyle Interventions to Promote Health in CKD .................................................. Room 109
Moderators: Kalani Raphael, Casey Rebholz
4:30 p.m. **SA-OR68** The Association Between Potassium Intake and Risk of CKD – Hyo Jeong Kim
4:39 p.m. **SA-OR69** Estimated Potassium Intake in Patients with CKD Is Associated with CKD Progression: The Fukuoka Kidney Disease Registry (FKR) Study – Tatsuya Suenaga
4:48 p.m. **SA-OR70** Association of Dietary Potassium and Fiber Intake with Death Risk in a Prospective Hemodialysis Cohort – Yoko Narasaki
4:57 p.m. **SA-OR71** Effects of a Whole-Food, Plant-Based Nutrition Education Program on Blood Pressure and Potassium Levels in CKD – Scott Liebman
5:06 p.m. **SA-OR72** Effect of Dietary Acid Reduction with Fruits and Vegetables vs. Oral NaHCO3 on Parameters of Cardiovascular Health in Stage 1 CKD: A 5-Year Randomized Trial – Nimrit Goraya
5:15 p.m. **SA-OR73** Food Insecurity, Dietary Intake, and Mortality Among Adults with CKD – Jenna Kiryakos
5:24 p.m. **SA-OR74** Dietary Inflammatory Potential and Kidney Function in the Hispanic Community Health Study/Study of Latinos – Tanya Johns
5:33 p.m. **SA-OR75** Personalized Patient Education on Lifestyle Modification and Nutrition Management in CKD Using ChatGPT – Prakrati Acharya
5:42 p.m. **SA-OR76** Intradialytic Cycling Exercise Improves Arterial Stiffness in Hemodialysis Patients – Ho-Hsiang Chang
5:51 p.m. **SA-OR77** Oxigen Consumption Recovery Is Delayed After the Long Interdialytic Period – Eliott Arroyo

Pediatric Nephrology: Clinical and Genetic Studies ............................................................................ Room 105
Moderators: Namrata Jain, Patricia Weng
4:30 p.m. **SA-OR78** Liddle Syndrome Caused by Loss-of-Function Mutations in the Ubiquitin Ligase NEDD4L – Daniela Rotin
4:39 p.m. **SA-OR79** Recessive Variants in MYO1C as a Potential Novel Cause of Nephrotic Syndrome – Ronen Schneider
4:48 p.m. **SA-OR80** Circulating Nephrin Autoantibodies Are Present in Almost 2/3 of Steroid-Naive Pediatric Idiopathic Nephrotic Syndrome – Astrid Weins
4:57 p.m. **SA-OR81** Unveiling the Disproportionate Impact of Rare Kidney Diseases on Kidney Failure: A Longitudinal Analysis Using the UK National Registry of Rare Kidney Diseases (RaDaR) – Daniel Gale
5:06 p.m. **SA-OR82** Contemporary Infant and Neonatal Dialysis (COINED) Study: Practice Patterns and Outcomes – Melissa Muff-Luett
5:15 p.m. **SA-OR83** Risk Factors and Impact of Peritoneal Podoplanin in Children on Chronic Peritoneal Dialysis – Maria Bartosova
5:24 p.m. **SA-OR84** Preliminary Findings from the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients with Selected Proteinuric Glomerular Diseases – Kenneth Lieberman
5:33 p.m. **SA-OR85** Assessing Baseline Cardiovascular Disease for Kids Initiating Kidney Replacement Therapy: ABCD4Kid Study – Priyanka Khandelwal
5:42 p.m. **SA-OR86** Molecular Pathways Associated with Early Vascular Calcification in Pediatric CKD – Julie Bernardor
5:51 p.m. **SA-OR87** Prospective Validation of the PERSEVERE-II AKI Prediction Model in Pediatric Septic Shock – Natalja Stanski
### Poster Topics

<table>
<thead>
<tr>
<th>Board #s</th>
<th>Poster Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFO01–INFO17</td>
<td>NIH/NIDDK and Informational Posters – III</td>
</tr>
<tr>
<td>001–026</td>
<td>Bioengineering: Modeling, Diagnosis, Therapy</td>
</tr>
<tr>
<td>027–069</td>
<td>Diversity and Equity: Other Research</td>
</tr>
<tr>
<td>070–106</td>
<td>AKI: Epidemiology, Risk Factors, Prevention – II</td>
</tr>
<tr>
<td>107–147</td>
<td>AKI: Biomarkers, Imaging, Interventions</td>
</tr>
<tr>
<td>148–194</td>
<td>AKI: Mechanisms – III</td>
</tr>
<tr>
<td>195–253</td>
<td>Onconephrology: Immunological Cross-Talk</td>
</tr>
<tr>
<td>254–295</td>
<td>Pharmacology: Kinetics, Genomics, Medication-Related Problems</td>
</tr>
<tr>
<td>296–319</td>
<td>Bone and Mineral Metabolism: Stones, Calcifications, Case Reports</td>
</tr>
<tr>
<td>320–354</td>
<td>Development, Organoids, Vascularized Kidneys, Nephrons, and More</td>
</tr>
<tr>
<td>355–395</td>
<td>Pediatric Nephrology – III</td>
</tr>
<tr>
<td>396–449</td>
<td>Diabetic Kidney Disease: Basic – II</td>
</tr>
<tr>
<td>450–493</td>
<td>Diabetic Kidney Disease: Clinical – II</td>
</tr>
<tr>
<td>494–542</td>
<td>Hypertension and CVD: Clinical – II</td>
</tr>
<tr>
<td>543–595</td>
<td>Hemodialysis: Biomarkers, Translational Research</td>
</tr>
<tr>
<td>596–625</td>
<td>Hemodialysis: Case Reports, Series, QI Projects</td>
</tr>
<tr>
<td>626–685</td>
<td>Home Dialysis – II</td>
</tr>
<tr>
<td>686–743</td>
<td>Fluid, Electrolyte, Acid-Base Disorders: Clinical – II</td>
</tr>
<tr>
<td>744–786</td>
<td>Genetic Diseases: Cystic - Genetic Analysis and Extrarenal Manifestations</td>
</tr>
<tr>
<td>787–821</td>
<td>Genetic Diseases: Glomerulopathies – II</td>
</tr>
<tr>
<td>822–867</td>
<td>Glomerular Diseases: From Inflammation to Fibrosis – III</td>
</tr>
<tr>
<td>868–926</td>
<td>Glomerular Diseases: Therapeutics</td>
</tr>
<tr>
<td>927–974</td>
<td>Glomerular Diseases: Translational Studies and Biomarkers</td>
</tr>
<tr>
<td>975–1024</td>
<td>Glomerular Diseases: Podocyte Biology – II</td>
</tr>
<tr>
<td>1025–1049</td>
<td>Pathology and Lab Medicine – II</td>
</tr>
<tr>
<td>1050–1092</td>
<td>Transplantation: Clinical – II</td>
</tr>
<tr>
<td>1093–1130</td>
<td>CKD Epidemiology, Risk Factors, Prevention – III</td>
</tr>
</tbody>
</table>

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.
As an ASN member, you are part of a vibrant global community of more than 20,000 kidney professionals. Stay connected to this innovative, supportive, and transformative community—join or renew your membership today to receive these exclusive benefits.

Maximize the value of your ASN membership with exclusive access to:

- A community of 20,000+ nephrology colleagues.
- Member discounts to ASN educational events, programs, and products.
- Access to ASN continuing education and career advancement tools.
- Eligibility for research grants and travel support.
- Subscription to In The Loop, a daily email collating kidney-related news.
- And much more.

Visit the ASN Member Services booth or www.asn-online.org/renew
A vital part of the Kidney Week educational experience is found on the scientific exposition floor, Exhibit Hall C, of the Pennsylvania Convention Center. This unparalleled international venue provides demonstrations of products and services that will enhance your understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care. On the exposition hall floor, you can engage in peer-to-peer interactions with representatives and businesses that form an integral part of your day-to-day fight against kidney disease and view thousands of accepted poster abstracts.

**Exhibition Schedule**

**Thursday**

November 2
9:30 a.m. — 2:30 p.m.

**Friday**

November 3
9:30 a.m. — 2:30 p.m.

**Saturday**

November 4
9:30 a.m. — 2:30 p.m.

Attendee Lounges are supported by Traver Therapeutics.

*Scientific Exposition Refreshment Breaks are supported by Novo Nordisk.*

*The Welcome Reception is supported by Calliditas Therapeutics.*
“We need to support a diversity of ideas. Progress comes from a good balance of disruptive research and incremental science.”

Laisel Martinez, PharmD, MS
University of Miami Miller School of Medicine
2023 KidneyCure Diversity, Equity, Inclusion, and Justice Research Scholar Grant Recipient

The trailblazing investigators funded by KidneyCure share your commitment to making a difference for the millions of patients impacted by kidney diseases. Bringing radical ideas and fresh perspectives, these determined grant recipients will advance care and find cures, such as Laisel Martinez, PharmD, MS, whose work aims to develop new anti-inflammatory therapies that will reduce vascular access failure to “improve health outcomes and the quality of life for dialysis patients.”

Your support is crucial to funding the diverse ideas that will progress our field.

Laisel Martinez, PharmD, MS, is the inaugural recipient of the KidneyCure Diversity, Equity, Inclusion, and Justice Research Scholar Grant. This grant is funded by Otsuka and Visterra, and the American Society of Nephrology.

Make a Difference
Use your phone’s camera to scan the QR code. Or visit: www.kidneycure.org/donate
On behalf of the 850,000,000 people worldwide with kidney diseases, the Cele Fogarty Travel Support Program for Patients ("Cele’s Champions") honors people living with kidney diseases or caring for an individual with kidney diseases by supporting their voice and advocacy.

Cecilia “Cele” Agnes Fogarty was a leading executive in event management and member services for decades, advancing the work of several major organizations, including ASN, in health care, medicine, science, and other areas. She was renowned for her ability to manage the most complex meeting logistics, anticipate challenges, and meet unexpected crises—large and small—with aplomb and sometimes magic.

Despite being diagnosed with kidney disease herself, Ms. Fogarty continued to work towards “A world without kidney diseases,” including the strenuous onsite meeting management, due to the flexibility of peritoneal dialysis, and the support of her care team. Her dedication and persistence parallel the courage and diligence to live well with a chronic disease.

Patient advocates who speak out for the people worldwide with kidney diseases.

ASN is committed to including the patient voice throughout the organization and in its activities. To honor Ms. Fogarty, her commitment to mentorship, and her passion for accommodating all people regardless of the challenges they may face, ASN is pleased to announce the group of 2023 “Cele’s Champions” - patient advocates who speak out for the people worldwide with kidney diseases.

- Joshua Albright
- Thelma Barber
- John Bayton
- Alexis Conell
- Maribel Costel
- Arnold Davis
- Valen Keefe
- Roberta Reed
- Janet Tennyson
- Dominika Woch
**DAY-AT-A-GLANCE**  
Sunday, November 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 8:00 a.m. – 9:00 a.m. | Plenary: In Memoriam, ASN Midcareer Awards, State-of-the-Art Lecture  
ASN Business Meeting                                    | Hall A    |
| 9:30 a.m. – 11:30 a.m. | **Basic/Clinical Science Sessions**  
Future of T Reg Therapy in Transplantation  
Implementation: Breaking Barriers to Reach the Bedside | Room 105  
Room 109  |
|               | **Clinical Practice Sessions**  
Fluid Management in High-Risk Populations  
IgA Vasculitis: Updates, Progress, and Challenges  
Leveraging Technical Advances to Manage and Monitor Hypertension  
Peritoneal Dialysis: How Much Is Adequate and How Can We Improve? | Room 201  
Room 204  
Room 113  
Room 111  |
|               | **Translational Sessions**  
APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases  
Complement as a Target in CKD  
Potential Markers for Prediction of Kidney Outcomes | Room 107  
Room 108  
Room 103  |

**Kidney Week On-Demand**

Never miss a session with Kidney Week On-Demand 2023. With over 200 hours of recorded Annual Meeting presentations, Kidney Week On-Demand is the best way to get the most out of your Annual Meeting experience.

To get your complimentary access code, exchange this voucher at the following booth:

Booth 2005

All recorded presentations will be available in late November 2023 on the ASN eLearning Center for up to three years. Final hours available subject to speaker permission. Access codes are available during Exhibit Hall hours to fully paid Annual Meeting participants only.

Program is subject to change.
Sunday, November 5, 8:00 a.m. – 9:00 a.m.

**Plenary** .............................................................................................................................................. Hall A
8:00 a.m. In Memoriam
8:05 a.m. ASN Midcareer Awards
8:15 a.m. State-of-the-Art Lecture “Too Hot: Human Bodies and Inhuman Temperatures” – Bill McKibben

**ASN Business Meeting** .............................................................................................................................................. Hall A

Sunday, November 5, 9:30 a.m. – 11:30 a.m.

**Future of T Reg Therapy in Transplantation** .......................................................................................................................... Room 105
Moderators: Anil Chandraker, Jonathan Maltzman
9:30 a.m. Epigenetics, Tregs, and Transplant Survival – Wayne Hancock
10:00 a.m. Regulatory T Cell Therapy in Kidney Transplantation: Where Do We Stand? – Joseph Leventhal
10:30 a.m. Engineering Regulatory T Cells to Induce Tolerance – Megan Levings
11:00 a.m. T Reg-Mediated Regulation of Immunity Within Allografts – Geoffrey Camirand

**Implementation: Breaking Barriers to Reach the Bedside** .......................................................................................................................... Room 109
ASN thanks the ASN AKINow Basic Science Workgroup for assistance with this session.
Moderators: Sherry Mansour, Mark Okusa
9:30 a.m. Recruiting Patients as Champions in Their Care: Identifying Barriers and Promoting Self-Advocacy – Patrick Gee
10:00 a.m. Reviewing the Science: Innovations in Kidney Care – Amy Mottl
10:30 a.m. Applying the Science: Implications for Kidney Transplant Patients – Vineeta Kumar
11:00 a.m. Uniting the Science and Bedside Care: Practical Approaches for the Kidney Care Team – Samir Parikh

**Fluid Management in High-Risk Populations** .......................................................................................................................... Room 201
Moderators: Michael Connor, Kathleen Liu
9:30 a.m. Approach to Fluid Balance Management in Intensive Care Unit Patients with AKI – Anitha Vijayan
10:00 a.m. Fluid Balance Management in Acute Hypoxemic Respiratory Failure Caused by Acute Lung Injury – Marlies Ostermann
10:30 a.m. Does the Use of Hypertonic Saline with Diuretics in Acute Heart Failure Improve Outcomes? – Kianoush Kashani
11:00 a.m. Perioperative Fluid Management in Patients Undergoing Major Surgery – Alexander Zarbock

**IgA Vasculitis: Updates, Progress, and Challenges** .......................................................................................................................... Room 204
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Leal Herlitz, Mahmoud Kallash
9:30 a.m. Updates in the Histologic Classification of IgA Vasculitis – Mark Haas
10:00 a.m. IgA Vasculitis: Similarities and Contrasts with IgA Nephropathy in Pathogenesis and Management – Jonathan Barratt
10:30 a.m. Secondary IgA Vasculitis: Drugs and Associated Systemic Diseases – Camille Rasmussen
11:00 a.m. IgA Vasculitis: A Different Disease in Children and Adults? – David Selewski

EDT to EST Time Change Sunday, November 5
Don’t forget to turn back your clocks one hour.
### Sunday, November 5, 9:30 a.m. – 11:30 a.m.

**Leveraging Technical Advances to Manage and Monitor Hypertension**

**Room 113**

**Moderators:** Sandra Taler, Raymond Townsend

- **9:30 a.m.** *Volume Management to Treat Hypertension in Patients with Kidney Diseases* – Jennifer Flythe
- **10:00 a.m.** *BP Targets in Patients Treated with Hemodialysis* – Chi-yuan Hsu
- **10:30 a.m.** *Systolic BP Time in Target Range and Major Adverse Kidney and Cardiovascular Events* – Leo Buckley
- **11:00 a.m.** *Cuffless BP Devices: Ready for Prime Time?* – Jordana Cohen

**Peritoneal Dialysis: How Much Is Adequate and How Can We Improve?**

**Room 111**

*ASN thanks the ASN Home Dialysis Steering Committee for assistance with this session.*

**Moderators:** Rafia Chaudhry, Thomas Golper

- **9:30 a.m.** *Peritoneal Dialysis Adequacy Beyond Kt/V_urea: How Much Is Enough?* – Joanne Bargman
- **10:00 a.m.** *Quality of Life on Peritoneal Dialysis: What Should We Consider?* – Nicole Scholes-Robertson
- **10:30 a.m.** *Fluid and Solute Transport: Can We Get More Out of the Peritoneal Membrane?* – Alena Parikova
- **11:00 a.m.** *Incremental Peritoneal Dialysis: The Hallmark of Individualizing Therapy* – Jenny Shen

**APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases**

**Room 107**

**Moderators:** Kaye Brathwaite, Patrick Brophy

- **9:30 a.m.** *Molecular Mechanisms of Extrakidney Manifestations of Hereditary Nephrotic Syndrome* – Nina Mann
- **10:00 a.m.** *Integrating APOL1 Testing into Clinical Practice* – Kate Bramham
- **10:30 a.m.** *The Many Faces of HNF1B Mutations* – Claudia Izzi
- **11:00 a.m.** *Common Variants in Mendelian Disease Genes as Risk Factors for CKD* – Tomoko Horinouchi

**Complement as a Target in CKD**

**Room 108**

**Moderators:** Richard Coward, Zaipul Md Dom

- **9:30 a.m.** *Complement Role Across Kidney Diseases* – Joshua Thurman
- **10:00 a.m.** *Complement Activation in IgA Nephropathy* – Matthew Pickering
- **10:30 a.m.** *Complement Role in Diabetic Kidney Disease: Emerging Evidence* – Melinda Coughlan
- **11:00 a.m.** *Complement Inhibition: Toward Translation* – Giuseppe Remuzzi

**Potential Markers for Prediction of Kidney Outcomes**

**Room 103**

**Moderators:** Josef Coresh, Sri Lekha Tummalapalli

- **9:30 a.m.** *Prediction Models to Predict Incident Kidney Diseases* – Navdeep Tangri
- **10:00 a.m.** *Proteomics for Predicting Outcomes in CKD* – Ruth Dublin
- **10:30 a.m.** *Precision Medicine in the Prediction of Kidney Disease Progression in Diabetes* – Steven Coca
- **11:00 a.m.** *Insights into the Genetic Basis of Early-Onset CKD* – Friedhelm Hildebrandt
TOP POLICY AND QUALITY VICTORIES IN 2023

1. Increased access to transplant care by passing the Securing the US OPTN Act, supporting the implementation of the Health Resources and Services Administration OPTN Modernization Initiative, and advancing legislation to better support living donors.

2. Engaged the kidney health community to support a screening recommendation for kidney diseases from the United States Preventive Services Task Force.

3. Advocated for consistent federal funding of innovation through KidneyX, kidney research at the National Institute of Diabetes and Digestive and Kidney Diseases and across the federal government, kidney disease surveillance at the Centers for Disease Control and Prevention, and care of American service members at the Veterans Health Administration.

4. Increased awareness about kidney diseases and the challenges faced by the kidney care workforce among policymakers at local events with members of Congress and the Biden Administration.

5. Advanced equity within kidney health by obtaining congressional support for studying transplant disparities, advocating for regulatory changes to increase access to home dialysis and further measure and integrate social determinants of health, and raising awareness about the impact of climate change on kidney health.

To learn more visit www.asn-online.org/policy
 ASN Excellence in Patient Care (EPC) focuses on clinical priorities to provide high-quality care for people with kidney diseases. Through all projects and initiatives, EPC aims to:

- Ensure all people with kidney diseases receive the best evidence-based care possible.
- Champion patient experiences, preferences, and values by actively engaging people with kidney diseases in EPC activities.
- Advance equitable access to high-quality kidney care by promoting diversity, equity, and inclusion and pursue health care justice.

Excellence in Patient Care (EPC), on behalf of the American Society of Nephrology (ASN), extends its gratitude to the leaders and volunteers of the EPC committees and workgroups. Learn more about EPC, and the Kidney Week sessions that feature its initiatives, at epc.asn-online.org or scan the QR code.
The Research, Discovery, and Innovation (RDI) department of the ASN Alliance for Kidney Health integrates three programs to stimulate, accelerate, and support biomedical research and innovations for people with kidney diseases.

- **KidneyCure** encourages and supports the kidney research and education workforce through grants and fellowships to pre-doctoral through early-career researchers.

- **Kidney Health Initiative** promotes the development of innovative treatment options for people with kidney diseases through a partnership among ASN, the US Food and Drug Administration, and more than 80 member organizations.

- **KidneyX** is a partnership between ASN and the US Department of Health and Human Services that enables the development of breakthrough treatments in kidney care.

Visit www.asn-online.org to learn more about ASN’s work to increase the nephrology workforce pipeline and foster innovation in kidney care.
Medical Resources and Platforms: Partnering With Experts in the Field

GSK is proud to partner with experts in the field to bring you medical education platforms to support you and your patients.

**Anemia of Chronic Kidney Disease YouTube Channel**
https://www.youtube.com/@anemiaofckd/featured

Visit the YouTube channel to view animations and expert presentations covering important topics including:
• Burden and prevalence of anemia of CKD in dialysis patients
• Latest understanding of the pathophysiology of anemia of CKD including the role of the HIF pathway
• Current management landscape and challenges within the dialysis patient population

Visit the YouTube channel to find out more!

**USMA Nephrology Portal**
https://gskusmedicalaffairs.com/nephrology/

Navigate and explore the latest disease education on anemia of CKD and lupus nephritis through:
• Infographics
• Expert videos
• Slide presentations
• Podcasts

Visit the USMA portal to learn more!

CKD, chronic kidney disease; HIF, hypoxia-inducible factor; USMA, United States Medical Affairs
These are non-promotional disease awareness websites and programs intended for US healthcare professionals only. They are not Continuing Education activities.
Ahead of Kidney Disease Together

Come visit us at
BOOTH #1630